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but to date there is surprisingly little evidence to support this assumption. In the Netherlands, 
there are regional professional networks (the so-called ParkinsonNet networks) which consist of 
specifically trained health professionals who treat large numbers of PD patients and who col-
laborate well with other professionals within the network.15 16  ParkinsonNet networks have been 
specifically developed to improve the PD-specific expertise of health professionals, to increase 
the patient volume per participating therapist, and to enhance communication and collabora-
tion between professionals.16 A large cluster-controlled trial has shown that the ParkinsonNet 
concept achieves these goals, and also leads to a substantial cost reduction that may be as high 
as 1400 Euros per patient per year.15
PHYSICAL INACTIVITY
 Many patients with PD lead a sedentary lifestyle. Overall, PD patients are 29% less physically 
active in comparison with age-matched controls. This reduced level of physical activity is parti-
cularly observed in patients with advanced disease.17 The motor and non-motor features of PD 
contribute directly or indirectly to this sedentary lifestyle. Being physically inactive is likely to have 
deleterious consequences for PD patients, for various reasons. A sedentary lifestyle is one of the 
leading causes of death among individuals in the general population18 and is associated with an 
increase in all-cause mortality.18 19 Lower levels of physical activity are a modifiable risk factor 
for several chronic diseases like type 2 diabetes mellitus, cancer, obesity, hypertension, bone 
and joint disease (osteoporosis and osteoarthritis), and depression.19 20 Furthermore, physical 
inactivity could increase the risk of cardiovascular disease directly.19 20  In one study, three weeks 
of bed rest caused a greater deterioration in cardiovascular and physical working capacity than 
did 30 years of aging.21 Finally, the sedentary lifestyle of PD patients could lead to a worsening 
of specific symptoms that are already present because of the disease itself; examples include 
insomnia, constipation, and depression.
REASONS WHY PARKINSON PATIENTS SHOULD BECOME 
MORE ACTIVE
 Patients with PD have many reasons to become (more) physically active. In general, physical 
activity reduces the risk of cardiovascular disease, cancer and osteoporosis.19 Physical activity 
could also have potential disease-specific effects, for example by improving cognitive dysfunc-
tion and mood.22-24 Animal studies indicate that exercise can prevent and decelerate the deve-
lopment of experimental parkinsonism through several mechanisms that involve neural plasticity 
of the dopaminergic and glutamatergic system.25-28 This is further supported by studies that 
investigated the relationship between physical activity and the risk of developing PD in humans, 
which have shown that moderate to vigorous exercise may protect against later development 
PARKINSON’S DISEASE
 Parkinson’s disease (PD) is a progressive neurodegenerative disorder. The prevalence is estima-
ted to be about 1.3% to 1.5% for persons above the age of 60 years in Europe.1 The number of 
individuals with PD will have doubled by the year 2030.2 PD results from an accelerated loss of 
dopamine-producing cells in the substantia nigra, a sentinel node in the basal ganglia circuitry. 
The resultant dopamine depletion leads to a number of typical motor features. During life the 
diagnosis of PD is clinically based, but the ultimate confirmation of the PD diagnosis requires 
neuropathological investigations. The presence of typical motor features (asymmetrical resting 
tremor, bradykinesia, or both), often in combination with rigidity and postural instability, exclu-
sionary symptoms, and response to levodopa is required to meet established clinical criteria.3 
Some additional clinical features and auxiliary investigations allow, to a large extent, a diffe-
rentiation between PD and the closely related forms of atypical parkinsonism.4 Besides these 
motor symptoms, PD is also characterized by a wide variety of non-motor symptoms such as 
depression, fatigue, autonomic dysfunction, cognitive decline, and sleep disturbances.5  Non-
motor symptoms generally correlate with advancing age and disease severity, although some of 
these (most notably constipation, insomnia and REM sleep behavior disorder) can occur early 
in the course of the disease, or might even become manifest before the motor symptoms.6 PD is 
a complex and thereby incapacitating disease. As a result, many PD patients carry a relatively 
heavy illness burden in the physical, mental and social dimensions of health-related quality of 
life compared with many other neurological or chronic conditions.7
MANAGEMENT OF PD
 Currently, there is no cure for PD. The treatment of PD  is therefore symptomatic, and primarily 
involves dopaminergic medication.8 Deep brain surgery is an alternative, but this is only availa-
ble for a selective group of patients whose symptoms are dopamine responsive but who expe-
rience debilitating response fluctuations.9  There is also a wide variety of non-pharmacological 
treatment options, including physical therapy*, occupational therapy, and speech and language 
therapy. The evidence to support these interventions is gradually growing, and treatment guide-
lines (partially based on evidence, partially on practical clinical experience) for some of these 
allied health care interventions have been developed.10-12 Integrating these various treatment op-
tions into a bundled multidisciplinary approach (along with pharmacological and surgical treatment) 
is widely felt to represent an optimal therapeutic strategy for this complex, multifaceted disease,13 14 
* In the Netherlands, the content of the evidence-based guideline for physiotherapy in PD is identical to the guidelines  for 
Cesar exercise therapists and Mensendieck exercise therapists. Therefore, the term ‘physiotherapy’ also includes Cesar and 
Mensendieck exercise therapies.
12 13
promotion of physical activity in parkinson's disease • feasibility and effectiveness general introduction and outline of this thesis 0101
OUTLINE OF THIS THESIS
 This thesis on physical activity and exercise in PD patients aims to develop better insight into 
the benefits, risks, and measurements of physical activity and exercise in PD, and to develop an 
approach that stimulates PD patients to lead a sustained, active lifestyle. 
 Chapter 2 provides an overview of all potential benefits and risks of physical activity in patients 
with PD. One of the general benefits of physical activity is the prevention or reduction of osteo-
porosis. In Chapter 3, the prevalence of osteoporosis and possible risk factors associated with 
bone loss in sedentary PD patients are investigated. In Chapter 4, we give an overview of the 
clinical evidence, pathophysiology and treatment of osteoporosis in patients with PD. 
 The quantitative assessment of physical activity is a complex issue. In Chapter 5, the validation 
of an ambulatory monitor to measure walking distance in PD patients is described. A method 
to assess physical fitness is described in Chapter 6. This chapter reports on the cardiovascular 
response to a submaximal exercise test in PD patients. Furthermore, physical fitness and test 
performance of PD patients were compared with healthy controls. The results of a randomized 
controlled trial that studied the effects of a multifaceted behavioral change program, the ParkFit 
program, to increase the level of physical activity in PD patients are presented in Chapter 7. 
Finally, the implementation of the ParkFit program is evaluated in Chapter 8.
of PD.29 30 Increasing physical activity in PD could also have some risks. PD patients have an 
increased risk of falls and fall-related injuries.31 In the general population, more active men and 
women have a higher incidence rate of leisure time and sport-related injuries than less active 
adults.32 Furthermore, exercise is associated with an increased risk of cardiovascular compli-
cations.32 However, compared to sedentary counterparts and those with low aerobic fitness, 
physically active or aerobically fit individuals have 25% to 50% lower overall risk of developing 
cardiovascular disease.33
THE CHALLENGE OF BEHAVIORAL CHANGE
 Although virtually everyone appreciates the potential merits of exercise, simply informing sub-
jects about such health benefits is not enough to change their behavior and to reach a sustained 
healthy lifestyle.34 Apparently, it is very difficult for people to give up their unhealthy behavior. 
Even patients who developed lifestyle-related illnesses, such as diabetes, have a hard time to 
reverse their unhealthy lifestyle. A real and sustained behavioral change is needed to achieve a 
physically active lifestyle for longer periods of time. In PD patients, several specific barriers exist 
to become and remain physically active, such as their motor symptoms (gait and balance pro-
blems) and non-motor symptoms (like apathy, fatigue, depression, and cognitive dysfunction). 
To change a sedentary lifestyle into an active lifestyle for longer periods of time, it is necessary 
to indentify and overcome these barriers to physical activity.34 One possible solution is that PD 
patients might benefit from receiving specific coaching and counseling when attempting to in-
crease their levels of physical activity.
 There are several theories about exercise behavior, including the health belief model, the social 
cognitive theory, and the transtheoretical model.35 Evidence shows that physical activity inter-
ventions should be targeted at several principles of behavioral change.34 Major factors to ascer-
tain a sustained behavioral change include: social support from family and friends; self-efficacy; 
an individually tailored program; activities that reflect the person’s preferences and capabilities 
(as these contribute to greater adherence); goal setting, using for example a health contract; 
regular performance feedback; and positive reinforcement.34 
02HOW MIGHT PHYSICAL ACTIVITY
BENEFIT PATIENTS 
WITH PARKINSON’S 
DISEASE? 
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ABSTRACT
 PD is a neurodegenerative disorder characterized by progressive motor and nonmotor impair-
ments. These impairments incline many patients towards a sedentary lifestyle, which has many 
deleterious consequences. Accumulating evidence suggests that patients with PD might benefit 
from physical activity and exercise in a number of ways, from general improvements in health to 
disease-specific effects and, potentially, disease-modifying effects (suggested by animal data). 
Many issues remain to be addressed, including the need to perform clinical trials to demonstrate 
these presumed benefits of physical activity and exercise in patients with PD. These trials must 
also address safety issues, such as an increased risk of falls and cardiovascular complications in 
more-active patients. Identifying ways to induce a sustained behavioral change, using specifi-
cally tailored programs that address potential barriers such as depression, apathy and postural 
instability, may lead to an improved quality of life in individuals with PD. 
PD is a neurodegenerative condition charac-
terized by progressive motor symptoms, includ-
ing gait disturbances and balance instability. 
Patients with PD can also develop a range of 
nonmotor complications, such as depression, 
apathy, sleep disturbances, constipation, and 
cognitive dysfunction. Together, these motor 
and nonmotor impairments might encourage 
the individual to adopt a sedentary lifestyle.17 36 
This response creates a vicious circle, because 
physical inactivity can negatively affect several 
clinical domains of PD (Figure 2.1). 
A sedentary lifestyle may represent more than 
just a consequence of PD; it could reflect a 
deliberate compensatory strategy to prevent 
further complications, observed for example in 
patients with severe postural instability who try 
to avoid falls by staying indoors. Indeed, fear of 
falling is common in patients with PD, and might 
result in a reduction in their outdoor physi-
cal activities.31 The positive effect of exercise 
on the healthy human brain has been studied 
extensively (Box 1) but evidence demonstrating 
the benefits of physical activity specifically in 
patients with PD is limited. Throughout this arti-
cle, ‘exercise’ refers to planned physical activity 
undertaken specifically to maintain or improve 
physical fitness and functional capacity.37 38 
Participation in exercise, as well as normal daily 
physical activities, results in improved physical 
fitness in healthy individuals as well as those 
with PD. This state of well-being carries a low 
risk of premature health problems, and pro-
vides the individual with energy to participate 
in an extended range of physical activities.38 
In this Perspectives article, we extrapolate from 
data on healthy populations, and evidence 
from clinical trials in patients with PD and other 
neurological conditions, to present and explore 
10 potential reasons why an active lifestyle 
might benefit patients with PD (Box 2). Possible 
risks associated with increased physical activity 
in patients with PD are also discussed, along 
with the imminent challenges that must be ad-
dressed to achieve a sustained, active lifestyle 
for this group of patients.
INTRODUCTION
POTENTIAL BENEFITS OF EXERCISE 
IMPROVING COGNITIVE FUNCTION 
 Cognitive impairment is common in individuals in the advanced stages of PD (up to 80% of 
patients will eventually develop dementia)47, and findings from the past 5–6 years suggest that 
cognitive decline actually begins early in the course of disease.48 Only two small studies have 
investigated the benefits of an aerobic exercise program on cognitive dysfunction in patients 
with PD.49 50 One of these studies investigated the effects of a multimodal physical exercise 
program in 20 patients with PD. The participants were assigned to either an intervention group 
(who received general physical training for 6 months) or a control group. The results showed 
a beneficial effect of training on executive function.49 The other study evaluated the benefits of 
exercise in 28 patients with PD, who were allocated to either an intervention program of twice-
weekly exercise for 12 weeks or a control group. The researchers concluded that exercise had 
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selective benefi ts on cognitive functioning by improving frontal-lobe-based executive function.50 
Additional evidence from studies in elderly individuals and patients with Alzheimer disease sug-
gests that exercise may postpone cognitive deterioration22 and delay the onset of dementia.23 
The aerobic component of exercise, in particular, drives these clinical effects.51 These promising 
results should now be explored further in large trials of exercise in patients with PD. 
ARREST OF OSTEOPOROSIS 
 The prevalence of osteoporosis is high in patients with PD: up to 63% of women with PD and 
20% of men with PD have this condition.52 53 By comparison, in age-matched healthy populati-
ons the prevalence of osteoporosis is 29% in women and 12% in men.54 Several factors might 
contribute to accelerated bone loss in patients with PD, such as physical inactivity, vitamin D 
FIGURE 2.1
THE VICIOUS CYCLE OF PHYSICAL INACTIVITY IN PD
 Patients with PD tend to lead a sedentary lifestyle, owing to a combination of motor and nonmotor features. A se-
dentary lifestyle has various adverse effects (solid arrows): secondary worsening of PD-related symptoms and signs 
(for example, constipation can worsen because of physical inactivity);  development or worsening of comorbidities 
and complications (such as cardiovascular disease); and increased mortality risk. In addition, by extrapolation from 
studies in rodents with experimentally induced parkinsonism we speculate that a sedentary lifestyle could negatively 
infl uence the course of PD itself (dotted arrow). Abbreviation: PD, Parkinson disease.
BOX 1
THE EFFECTS OF EXERCISE ON THE HUMAN BRAIN
 The benefi cial effects of physical activity on brain functions in healthy people presumably work via adaptive neu-
roplasticity—the brain’s capacity to adjust through dynamic neuronal reorganization.37 Studies in healthy older 
rodents have shown that regular aerobic activity triggers plasticity-related changes in the CNS, including synapto-
genesis, enhanced glucose utilization, angiogenesis, and neurogenesis.39 In older adults who are free of cognitive 
impairment, aerobic exercise promotes brain health by reducing infl ammation, suppressing oxidative stress, and 
stabilizing calcium homeostasis.40 Furthermore, release of endogenous neurotrophins (such as brain-derived neu-
rotrophin, glia-derived neurotrophin factor, nerve growth factor, and galanin) during regular aerobic exercise is 
associated with synaptic plasticity and enhanced cognitive performance, learning and memory.41 42
 Several imaging studies have underpinned the benefi cial cerebral effects of exercise in humans. For example, ae-
robic fi tness increased the volume of gray and white matter in sedentary people.43 Furthermore, increased physical 
activity (achieved via cognitive behavioral therapy) produced an increase in gray matter volume in patients with 
chronic fatigue syndrome.44 Currently, no data are available as to whether exercise can induce structural or func-
tional brain alterations in patients with PD, and at what level potential neuroplastic changes might occur. Adaptive 
neuroplasticity can occur spontaneously in patients with PD, at the level of both the basal ganglia and the cortex,45 
and such compensatory processes may even start in the preclinical phase.46 Studies to determine whether exercise 
can drive or facilitate these processes should be high on the research agenda.
BOX 2
POTENTIAL BENEFITS OF EXERCISE  
The 10 possible benefi ts of exercise in patients with PD are as follows:
 Prevention of cardiovascular complications
 Arrest of osteoporosis
 Improved cognitive function
 Prevention of depression
 Improved sleep
 Decreased constipation
 Decreased fatigue
 Improved functional motor performance
 Improved drug effi cacy 
 Optimization of the dopaminergic system
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deficiency, muscle weakness, low body weight, and hyperhomocysteinemia. Most of these factors 
evolve during the course of PD and reinforce each other. Patients with PD also have a high risk of 
falling31 which, in combination with osteoporosis or osteopenia, increases the risk of fall-related frac-
tures.55 Prevention or reduction of osteoporosis would, therefore, be of great benefit for individuals 
with PD. 
 Conversely, physical activity and exercise are associated with improved bone health.56 Although 
the optimal training method for stimulating bone growth in adults has not yet been defined, 
evidence points to a combination of high-impact activities such as jumping, and weight-bearing 
exercises such as sprinting, jogging or stair climbing.57 Whether patients with PD can improve 
their bone health by adapting to a physically active lifestyle, or by following an exercise program, 
remains to be demonstrated in appropriately designed studies. The high-impact exercises re-
quired to examine this effect may not be suitable for all patients, owing to their high risk of falls; 
less-hazardous weight-bearing exercises such as regular walking, aerobics or dancing may be 
more appropriate for patients with PD.
PREVENTION CARDIOVASCULAR EVENTS
 The precise incidence of cardiovascular events, such as myocardial infarction or cerebrovascular 
disease, is unclear in patients with PD. In general, cardiovascular risk factors (including diabetes, 
a history of smoking, hypertension, and high cholesterol levels) are less common in patients with 
PD than in controls.58 A review suggested that patients with PD might have an increased propensity 
to develop comorbid cerebrovascular complications,59 but more work is needed to confirm this 
association.
 A sedentary lifestyle is one of the leading causes of death among individuals in the general po-
pulation.18 In addition, the amount of physical activity is inversely related to all-cause mortality.18 
In particular, exercise training positively influences cardiovascular risk factors and reduces the 
incidence of cardiovascular disease (including cerebrovascular events).60 The American College 
of Sports Medicine and the British Association of Sports and Exercise Sciences recommend, 
therefore, that all healthy adults aged between 18 and 65 years old should regularly participate 
in physical activity to promote and maintain health.32 61 Prospective studies suggest that adhe-
rence to this recommendation is associated with reductions of 20–30% in the risk of cardiovas-
cular disease.62 The general benefits of physical activity and exercise can also be expected to 
apply to individuals with PD; however, such effects remain to be demonstrated in this population. 
In terms of intrinsic capacity to engage in exercise, studies have shown that the maximal oxygen 
uptake of patients with PD was no different from that of controls, but men with PD reached their 
maximal oxygen uptake earlier than did controls, suggesting less mechanical efficiency of move-
ment during exercise, perhaps due to their muscle rigidity.63 This earlier saturation of maximal 
oxygen consumption indicates that patients with PD must stop exercising earlier than controls.
PREVENTING DEPRESSION 
 The relationship between physical activity and mental health has been widely investigated in 
populations without PD. A systematic review of 11 randomized controlled trials concluded that 
exercise is an effective treatment for depression in healthy individuals,24 although the underlying 
mechanisms remain poorly understood.
 Depression is a common neuropsychiatric symptom associated with PD. The prevalence of de-
pression depends on the patient’s age and the severity of their motor symptoms, increasing from 
15.6% in Hoehn and Yahr stages I–II, to 47.9% in stages IV–V.64 Several studies have also exa-
mined the effect of a physical activity intervention on depression in patients with PD. One study 
reported a statistically significant improvement in depression in the group who had received the 
intervention, as compared to a group with no intervention or a massage group,65 whereas other 
studies reported no clear improvement in depression with exercise.49 66-68 The reader should 
note that depression has mostly been included as an exploratory outcome in studies involving 
patients with PD. Large clinical trials are needed to examine the benefit of physical exercise 
specifically on depression in this population. 
IMPROVED SLEEP 
 Sleep dysfunction occurs in two-thirds of patients with PD, among whom the most common pro-
blem is frequent night-time awakening.69 In a small, non-controlled study of 20 patients with PD, 
some indication of sleep improvement was seen in those who participated in 36 group sessions 
of aerobic exercises and muscular strengthening.70 In the general population, sedentary elderly 
individuals with moderate to severe sleep dysfunction showed improvements (assessed by the 
Pittsburgh Sleep Quality Index) in sleep-onset latency and sleep duration after moderate-inten-
sity exercise.71 To assume that exercise could also improve sleep-related disorders in patients 
with PD seems reasonable; however, this area clearly needs to be studied in more detail. 
DECREASED CONSTIPATION 
 Constipation is the most common gastrointestinal symptom in individuals with PD, and is repor-
ted by 50–80% of patients.72 Although the causes of constipation in patients with PD are multi-
factorial, this symptom is in part attributable to a lack of physical exercise.73 No studies have yet 
evaluated the influence of exercise or increased physical activity on constipation in patients with 
PD; however, we might reasonably expect that patients with PD would experience similar bene-
fits to those seen in healthy individuals, in whom cross-sectional studies have shown an inverse 
relationship between physical activity and the risk of constipation.74 The mechanisms underlying 
the positive effect of exercise on constipation are unclear, but could include increased colonic 
motility, decreased blood flow to the gut, biomechanical stimulation of the gut during bouncing 
movements (such as running) or compression of the colon by abdominal musculature, and in-
creased fiber intake as a result of increased energy expenditure.74
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DECREASED FATIGUE
 Fatigue is experienced by 30–50% of patients with PD;75 in a community-based population 
study, 44.2% of 233 patients with PD reported fatigue, compared with 18% of 100 age-matched 
controls.76 Longitudinal studies in the general population showed that the amount of physical 
activity undertaken was inversely correlated with the presence of fatigue.77 This pattern was also 
apparent in patients with PD.77 Results obtained from studies in patients with chronic fatigue syn-
drome showed that cognitive behavioral training effectively reduced fatigue; however, changes 
in physical activity did not reduce levels of fatigue.78   A review of nine randomized controlled 
trials found encouraging evidence that patients with chronic fatigue syndrome benefi t from 
exercise therapy, but also concluded that more studies are needed.79 If these fi ndings can be 
extrapolated to patients with PD, exercise training in patients with PD might be useful to avoid or 
reduce fatigue in this population, although there no data have been obtained from clinical trials 
to support this hypothesis. The other side of the coin is that exercise may paradoxically increase 
fatigue, so future trials should tailor the level of exercise to each patient’s individual capacity.
IMPROVED MOTOR PERFORMANCE
 Individuals with PD invariably experience functional decline in a number of motor domains, 
including posture, balance, gait, and transfers (such as moving between a bed and chair). 
Several studies, including systematic reviews and a meta-analysis, have evaluated the effects of 
exercise on these functional defi cits (Table 2.1). The overall conclusions of these studies were 
that exercise can improve physical functioning, health-related quality of life, leg strength, ba-
lance, posture, gait, and physical condition. The data showing that exercise improves functional 
motor performance in patients with PD seem robust; however, the question remains as to which 
exercise protocol is best suited for individual patients.
IMPROVED LEVODOPA EFFICACY
 Several studies80-83 have investigated the association between exercise and the pharmacokine-
tics of levodopa, one of the drugs most commonly used to treat the symptoms of PD. Levodopa 
is transported to the brain and converted to dopamine, which ameliorates the dopamine defi cit 
that occurs in patients with PD. Although most studies have found no effect of exercise on the 
effi cacy of levodopa,81 82 one report revealed a trend towards improved absorption of this drug 
during physical activity.83 In theory, exercise might stimulate levodopa absorption because of 
accelerated gastric passage or increased mesenteric blood fl ow.83 Alternatively, levodopa might 
cross the blood–brain barrier more effi ciently, due to higher blood pressure and heart rate 
during exercise.84 However, these prior studies only evaluated a single, brief bout of exercise 
(maximum 2 h). Clearly, further studies are needed, particularly of prolonged exercise interven-
tions, to assess the effect of exercise on the response to levodopa therapy in individuals with PD.
OPTIMIZED DOPAMINERGIC SIGNALING
 Exercise could potentially infl uence endogenous production and release of dopamine in patients 
with PD, leading to enhanced dopaminergic neurotransmission.85 This postulated mechanism is 
in line with behavioral studies that reported a positive effect of endurance exercise on both sim-
ple and more-complex movements in patients with PD, both of which were executed faster after 
exercise.86 Although no concurrent neuroimaging studies were performed, the authors specula-
ted that this improved performance could be attributed to an augmented synthesis and release 
of dopamine and other catecholamines in the prefrontal cortex, nucleus accumbens and basal 
ganglia.86 However, some researchers have expressed concern that, when exercising, the motor 
response of PD patients may be pushed towards more normal values and the motor system might 
use up the available levodopa faster, leading to a greater (or earlier) dopamine shortage in the 
hours following exercise. This hypothesis needs to be studied in detail.
PREVENTION OF PD 
 The preceding section dealt with how exercise might improve motor and nonmotor dysfunction 
in patients who have clinically overt PD. However, the fascinating possibility exists that physical 
activity or exercise could also postpone the onset of parkinsonism, or perhaps even prevent 
disease manifestations altogether, in asymptomatic individuals who are predisposed to develop 
BOX 3
THE PARKFIT STUDY
 Our research group designed the ParkFit program—a multifaceted intervention to promote physical activity in 
sedentary patients with PD. This intervention is being studied in the ParkFit trial, which will investigate whether this 
program affords increased levels of physical activity that persist for 2 years.87 The trial will also evaluate the possible 
health benefi ts and risks of increased physical activity.87
 The ParkFit trial is a multicenter, randomized controlled trial that will compare two different exercise interventions: 
physical therapy with a specifi c emphasis on promoting a physically active lifestyle (the ParkFit program); and mat-
ched physical therapy with a specifi c emphasis on the safety and quality of performing daily activities (the ParkSafe 
program). The ParkFit program emphasizes behavioral change, using a combination of accepted motivational 
techniques and strategies, and personal health coaches to induce a lasting increase in exercise behavior for patients 
with PD. The ParkFit program incorporates several specifi c elements: an educational workbook (including a health 
contract and logbook) designed to educate the patient about the benefi ts of physical activity, provide advice about 
suitable activities, help to identify and overcome perceived barriers to engagement in physical activity, and provide 
information on recruiting social support; a personal activity coach; goal setting; ambulatory monitoring with visual 
feedback; and physical therapy. The fi rst results of the trial are expected by the end of 2011.
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the disease. This issue is all the more pertinent because we are starting to identify people who 
are at an increased risk of developing PD: individuals with rapid eye movement sleep behavior 
disorder; family members (of individuals with PD) who have a reduced sense of smell; people 
with chronic constipation; or those who carry a mutation in a PD susceptibility gene.92 
 The holy grail in the fi eld of PD is to reliably identify these individuals as early as possible and to 
expose them to treatments that might slow down, or even arrest, the underlying disease process 
that will ultimately result in parkinsonism. Although such pre-emptive treatments are not yet 
available, we may logically assume that exercise could prove to be an intervention. This idea is 
further supported by epidemiological studies that investigated the relationship between physi-
cal activity and the risk of subsequently developing PD, and by studies in mouse models of PD 
that have highlighted the neuroprotective and neurorestorative effects of exercise.29 However, 
whether the association between exercise and risk of PD can be explained by a truly preventive 
effect of exercise on the development of PD, or by a decrease in baseline recreational activity as 
a result of preclinical PD, is not yet clear.30 
RISKS OF EXERCISE IN PD 
 Individuals with PD have an increased risk of falls and fall-related injuries, such as fractures.31 
The rates for falls and injuries might increase still further if these patients are stimulated to be-
come more active, as even in the general population physically active adults have a higher inci-
dence of leisure-time and sport-related injuries than their less active counterparts.32 In patients 
with PD, fall rates seem to taper off in the end stages of the disease, as the patients become 
progressively less mobile.31 
 Paradoxically, although exercise may increase the likelihood of falls in individuals with PD, 
it could also reduce the overall risk associated with falls and the associated fractures; for 
example, by improving strength, fi tness, bone density or overall balance.93 One study inves-
tigated the effects of a home-based exercise program in patients with PD. The results sug-
gested that this intervention tended to reduce the incidence of fall events and injurious falls.94 
Additional evidence came from the RESCUE study—a large, multicenter study of rhythmic 
somatosensory cueing, in which a vibrating cylinder attached to the wrist was used to improve 
gait in patients with PD.95 The researchers reported that the intervention led to improved mobi-
lity without an increased risk of falls.95 The case as to whether exercise increases the patient’s risk 
of falling is, therefore, far from closed; moreover, this issue should be considered in future trials.
 Exercise is also associated with an increased risk of cardiovascular complications. Although 
the risk of sudden cardiac arrest or myocardial infarction is very low in generally healthy 
adults during activities of moderate intensity, the risk of these events increases during vigorous 
physical activity, especially in sedentary individuals or those with pre-existing coronary artery 
disease.32 Nonetheless, physically active or aerobically fi t individuals enjoy a 25–50% reduc-
tion in their lifetime overall risk of developing cardiovascular disease.32  Comparable data 
are not available for patients with PD, but they are unlikely to be an exception to this general 
rule. However, the risk of comorbid cerebrovascular disease seems to be higher in patients 
with PD than in the general population.59 This increased risk is likely ameliorated by exercise, 
because regular moderate exercise has been shown to be a protective factor for development 
of cerebrovascular disease.59 Other potential adverse effects of exercise include increased 
fatigue and levodopa requirements, as discussed earlier.
BOX 4
EVIDENCE FROM ANIMAL STUDIES
 In rodent models of PD, which rely on administration of neurotoxins (6-OHDA or MPTP) to induce parkinsonian 
symptoms, exercise attenuates the degree of injury to midbrain dopaminergic neuron, and restores basal ganglia 
function through adaptive mechanisms of dopamine and glutamate neurotransmission.26-28 101 
 In rats, voluntary or forced exercise (on a running wheel or treadmill) initiated before or during the administration 
of 6-OHDA and continued for an additional 1–5 weeks afterwards leads to the preservation of neurons in the 
substantia nigra pars compacta and to the attenuation of terminal loss in striatal and nigrostriatal dopaminer-
gic neurons.28 101 Similarly, intensive treadmill exercise facilitates brain recovery in MPTP-treated mice, even 
when exercise commenced after neurotoxin-induced cell death was complete. These animals also demonstrated 
compensatory changes in the remaining dopaminergic neurons, such as altered dopamine handling (increased 
release and decreased uptake) and neurotransmission (increased  dopamine numbers of D2 receptors expres-
sion) in surviving dopaminergic neurons and their targets.102 
 
 Exercise may also reverse the increased glutamatergic drive characteristic of the parkinsonian state at the level 
of striatal medium spiny neurons, by modulating the subunit composition of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (a glutamate receptors subtype), and by diminishing the amplitude of the 
spontaneous excitatory post-synaptic potential at glutamatergic corticostriatal terminals. Several potential 
exercise-induced mechanisms of neuroprotection and neurorestoration exist at the cellular level: elevation of 
transcription factors; activation of signal transduction pathways; and the induction of neurotrophic factors, such 
as brain-derived neurotrophin and glia-derived neurotrophin.103 104  
 Abbreviations: 6-OHDA, 6-hydroxydopamine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
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Review Topic Numbers of: Criteria for inclusion Conclusions
Studies Patients
Goodwin et al. 
(2008)68*
Exercise 
or physical 
activity
14 RCTs 495 patients 
with PD
An exercise or physical 
activity intervention 
compared with any 
comparator
Outcomes included 
physical performance 
or functioning, falls or 
HRQOL
Exercise is effective 
at improving physical 
functioning, HRQOL, 
leg strength, balance 
and walking
Insuffi cient evidence 
that exercise improves 
falls and depression
Crizzle et al. 
(2006)88
Physical or 
therapeutic 
exercise
7 studies 
(including 3 
RCTs)
438 patients 
with PD
Interventions comprising 
physical or therapeutic 
exercise
Effects of physical exer-
cise were evaluated
Published in a peer 
reviewed journal
Patients improve physi-
cal performance and 
activities of daily living 
through exercise
Keus et al. 
(2007)89
Physical 
therapy
29 studies 
(including 23 
RCTs)
Not appli-
cable
Physical therapy
Only trials with suffi cient 
data
Core areas of physical 
therapy
Published in English, 
Dutch or German
Four specifi c recom-
mendations: cueing 
strategies to improve 
gait; cognitive move-
ment strategies to im-
prove transfer; exercises 
to improve balance; 
training of joint mobil-
ity and muscle power 
to improve physical 
capacity
Kwakkel et al. 
(2007)90
Physical 
therapy
23 RCTs 1,063 pa-
tients with PD
Core areas of physical 
therapy
Published in English, 
German or Dutch
Evidence in favor of 
specifi c task-oriented 
exercise training to 
improve posture, bal-
ance control, gait and 
gait-related activities, 
and physical condition
Mehrholz et al. 
(2010)91*
Exercise 8 RCTs 203 patients 
with PD‡
Treadmill training 
versus no treadmill 
training
Patients who receive 
treadmill training are 
more likely than those 
who do not to improve 
their impaired gait 
hypokinesia
 
TABLE 2.1
SUMMARY OF PUBLISHED REVIEWS ON THE EFFECT OF EXERCISE ON MOTOR DISABILITY IN PD
* Meta-analysis. ‡UK Brain bank criteria. Abbreviations: HRQOL, health-related quality of life; PD, Parkinson 
disease; RCT, randomized controlled trial.
CHANGING SEDENTARY LIFESTYLES
 Regular physical activity is commonly accepted to be an important component of a healthy 
lifestyle. However, simply informing people about the health benefi ts of physical activity is not 
enough to attain a sustained behavioral change, which might explain why so many citizens (not 
just patients with PD) lead a sedentary life. Inducing a lasting change in exercise behaviors of-
fers a particularly great challenge for patients with neurological disorders. In patients with PD, 
several specifi c barriers to such changes exist—not only the motor disabilities (gait and balance 
problems), but also the diverse nonmotor problems (cognitive decline, apathy, and depression). 
The progressive nature of these symptoms provides reasons to doubt whether patients with PD can 
be motivated to remain active in the long term.
 If a true behavioral change can be attained in patients with PD, they might need specifi c coaching 
and counseling (rather than the general advice given to healthy adults). Evidence shows that 
effective physical activity interventions in this group should incorporate behavioral change prin-
ciples.34 Social cognitive theories propose that the control of behavior is based on two types of 
expectations: self-effi cacy (individuals’ belief in their ability to perform actions to attain a desired 
outcome) and outcome expectations (the belief that a certain consequence will be produced by 
personal action).96 To change lifestyle and attain an enduring behavioral shift might, therefore, 
call for specifi c strategies tailored to the individual’s preferences and needs. These behavioral 
programs should focus on appropriate supervision and social support from spouses and care-
givers.97 98 Our research group has begun to address these issues in the ParkFit study (Box 3). 
Further research is needed to develop combined counseling and exercise programs for patients 
with PD, which focus on a behavioral change and have long-term follow-up. So far, the available 
studies have had no postintervention exercise-free period, and only short follow-up.99 100 Extended 
follow-up is important to evaluate whether the benefi cial effects of exercise persist, and whether 
a reduced-intensity maintenance exercise program is needed to uphold the effects. Other studies 
should try to separate symptomatic effects from potential disease-modifying effects. 
CONCLUSIONS 
 Compelling theoretical reasons support the avoidance of a sedentary lifestyle and the promo-
tion of physical activity (including muscle strengthening, aerobic exercise and weight-bearing 
exercise) for people with, or at risk of developing, PD. Currently, however, we lack adequate 
knowledge about the merits of exercise specifi cally in patients with PD. The best available evi-
dence stems from studies in healthy individuals or patients with other neurodegenerative disea-
ses, which suggest a benefi cial effect of exercise on cardiovascular mortality or morbidity18 and 
on cognitive dysfunction22 23 or mood.24 Animal studies have raised the fascinating possibility 
that exercise might exert a neuroprotective effect in experimentally induced parkinsonism (Box 
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4) but these findings have yet to be translated to the human disease. 
 Development of a reliable strategy to stimulate an active lifestyle in patients with PD will be es-
sential, and these efforts must pay careful attention to safety issues and each patient’s individual 
capacities. Such exercise programs must also consider various barriers that could impede an 
active lifestyle specifically in patients with PD, such as apathy, fatigue, depression and cognitive 
dysfunction. The primary aim of these approaches is to induce a sustained behavioral change, 
with the hope of providing symptomatic relief of both motor and nonmotor disability, and per-
haps to slow down progression in patients with overt PD. If exercise is proven to have disease-
modifying effects, the ultimate goal will be to deliver strategies to postpone, or possibly prevent, 
the first disease manifestations in asymptomatic populations at risk of developing PD.
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ABSTRACT
BACKGROUND
 Bone loss is more common in PD than in the general population. Several factors may be involved 
in the development of bone loss, including malnutrition, immobilization, low body mass index, 
decreased muscle strength, vitamin D deficiency and medication use. This study investigates the 
prevalence of osteoporosis and possible risk factors associated with bone loss in early stage PD.
METHODS
 In 186 PD patients (Hoehn and Yahr stage 1 - 2.5, mean age 64.1 years, 71% men) bone mine-
ral density (BMD) measurements were performed with DEXA. T- and Z-scores were calculated. 
Univariate linear regression analysis was performed to identify variables that contributed to 
BMD. 25-OH-vitamin D status of PD patients was compared with 802 controls (mean age 63.3 
years, 50% men) using linear regression analysis. 
RESULTS
 Osteoporosis (11.8%) and osteopenia (41.4%) were common in PD patients. Mean Z-score for 
the hip was 0.24 (SD 0.93), and for the lumbar spine 0.72 (SD 1.91). Female gender, low weight, 
and low 25-OH-vitamin D were significantly correlated with BMD of the hip and lumbar spine. 
PD patients had lower 25(OH)D serum levels than controls (B=-10, p=0.000).
CONCLUSION
 More than half of the patients with early stage PD had an abnormal BMD. Female gender, 
low weight, and low vitamin D concentration were associated with bone loss. Furthermore, 
vitamin D concentrations were reduced in PD patients. These results underscore the impor-
tance of proactive screening for bone loss and vitamin D deficiency, even in early stages of PD. 
METHODS 
SUBJECTS
 PD patients
 The study population consisted of subjects from the ParkFit study, a randomized controlled trial 
evaluating the effectiveness of a multifaceted behavioral change program to increase physical 
activity in sedentary PD patients. The rationale and study design have been described previ-
ously.87 Patients participating in the ParkFit study were invited to also participate in the present 
study. Data collection took place between September 2008 and January 2010. Eligibility criteria 
were: (a) PD, according to the UK Brain Bank Criteria3; (b) age between 40 and 75 years; (c) 
sedentary lifestyle defined as: <3 times a week vigorous-intensity physical activity for <60 mi-
nutes; or <3 times a week moderate-intensity physical activity for <150 minutes); (d) Hoehn and 
Yahr ≤2.5. Exclusion criteria were: (a) unclear diagnosis (no gratifying and sustained response to 
dopaminergic therapy); (b) MMSE <24); (c) unable to complete Dutch questionnaires; (d) severe 
co-morbidity interfering with daily functioning; (e) daily institutionalized care; and (f) deep brain 
surgery. Informed consent was obtained before the first assessment. All subjects gave written 
informed consent prior to the study, as approved by the local Medical Ethical Committee.
MEASUREMENTS PD PATIENTS
 Dual-Energy X-ray absorptiometry
 Between 0-6 months after inclusion of the ParkFit study patients received a dual-energy X-ray 
absorptiometry (DEXA). BMD measurements were performed with DEXA using a Hologic 
PD is a common and incapacitating disorder 
affecting a sizeable proportion of the age-
ing community. Patients with PD have an in-
creased risk of sustaining fractures.17 105 The 
main causes for fractures in PD are falls, 
due to underlying gait and balance disor-
ders, and a decreased bone mineral density 
(BMD).106 107 Bone loss appears to be more 
common in PD compared to the general 
population. Several factors may be involved 
in the development of bone loss, including 
malnutrition, physical inactivity, low body 
mass index, decreased muscle strength, vita-
min D deficiency and certain medications.53 
Furthermore, osteoporosis is an important 
risk factor for fragility fractures, which are as-
sociated with increased morbidity and mor-
tality. Therefore, screening for osteoporosis 
might need special attention in PD patients. 
Although several studies of bone loss in PD 
have been conducted, most studies included 
also patients with advanced disease (Hoehn 
and Yahr 3 or more).108-111 Moreover, etiologi-
cal factors have been reported entirely con-
sistently. This study evaluated the prevalence 
of osteopenia and osteoporosis in patients 
with early PD, and also studied possible risk 
factors associated with bone loss.
INTRODUCTION  
promotion of physical activity in parkinson's disease • feasibility and effectiveness
34 35
03bone mineral density and vitamin d status in parkinson's disease patients03
QDR1000. Scanning was performed according to the instructions of the manufacturer. Quality 
assurance, including calibration was performed routinely every morning for DEXA, using the 
standard provided by the manufacturer. BMD was measured at the femoral neck, trochanteric 
and intertrochanteric regions and in the first four lumbar vertebrae. The difference between an 
individual’s BMD and the mean for a reference population is expressed in standard deviation 
(SD) units. T- and Z-scores were calculated where the T-score is the SD of the individual BMD 
compared with the mean BMD score in a young healthy population and the Z-score is the SD 
of the individual BMD compared to the mean BMD score of a similar sex-, age-, weight- and 
height-matched population. We used the WHO classification range to categorize subjects as 
normal (T>-1), osteopenic (-2.5 < T≤ -1), or osteoporotic (T≤-2.5). 
 Physical activity 
 The level of physical activity was measured with a 7-day recall,  based on a interview-based 
physical activity questionnaire, the LASA Physical Activity Questionnaire (LAPAQ).112  Patients 
were asked to list their daily amount of activity (frequency and duration), so total time spent on 
physical activity (in hours per week) could be calculated.
 Isometric grip strength 
 Isometric grip strength was measured using an adjustable hand held dynamometer (JAMAR dyna-
mometer) at the non-dominant hand. The subjects were seated with their shoulder adducted and 
neutrally rotated. The dynamometer was held freely, without support. The elbow was flexed at 900 
and care was taken that it did not touch the trunk. The forearm was in a neutral position, and the wrist 
was held between 0-300 dorsiflexion and between 0-150 ulnar deviation. The subjects were told to 
put maximal force on the dynamometer. The maximal value of two trials was noted in kilograms. 
 Body composition
 Height and weight were measured in standing position without shoes. Body mass index (BMI) 
was calculated as the weight in kilograms divides by the square of heights in meters.
 Other variables
 A wide range of other variables was assessed: disease severity (Hoehn and Yahr staging113; mo-
tor section of the Unified Parkinson’s Disease Rating Scale (UPDRS))114, disease duration (date 
of diagnosis), mobility (Timed Up and Go test (TUG)) and gait speed (participants were timed 
while walking four meters at their normal pace).
 Participants were asked about current and past medication use. All participants were intervie-
wed about their smoking and alcohol habits. The participants were asked to complete question-
naires about diet and sunlight exposure. The mean weakly dietary calcium and vitamin D intake 
was calculated for each participant. Furthermore, serum samples of both calcium and vitamin 
D were measured. Since low levels of testosterone have been shown to have a detrimental ef-
fect on bone density in men we analyzed if testosterone levels were related to bone density. All 
patients were measured on dopaminergic medication.
 25-OH-vitamin D
 25-OH vitamin D (25(OH)D) levels were measured on the E170 modular (Roche Diagnostics, 
Mannheim, Germany) and compared with a reference group. The reference group consisted of 
402 independently living women115 and 400 independently living men.116  Their mean age was 
63.3 years (range 40-80). Vitamin D deficiency was defined as a 25(OH)D level of less than 50 
nmol/l.  
 X-rays
 X-ray radiographics of the spine and thoracal vertebrae were performed to asses vertebral 
compression fractures.
STATISTICAL ANALYSIS 
 Bivariate associations were determined using the chi-square test for categorical variables and 
the unpaired t-test for continuous variables. Univariate linear regression analysis was performed 
to study the association between the several factors mentioned above and BMD. Age, gender, 
height and weight were included in the analysis, as these factors may influence BMD. Linear 
regression analysis was used to investigate the 25(OH)D concentration between patients and 
controls after controlling for covariates age, gender, weight, height, smoking and alcohol con-
sumption. A significant level of 0.05 was set for all statistical tests.    
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RESULTS 
 Of the 586 PD patients included in the ParkFit study, 186 PD patients participated in the present 
study (Table 3.1). Characteristics of the PD patients in the ParkFit study and PD patients of the 
present study are presented in Table 3.2.  
BONE MINERAL DENSITY IN PD 
 The summed prevalence of osteoporosis and osteopenia was 53.2% (41.4% for osteopenia, 
11.8% for osteoporosis) in PD patients (Table 3.3). The mean Z-score for the hip was 0.24, and 
for the lumbar spine 0.72. 
DETERMINANTS OF  BMD
 Univariate regression analyses showed that female gender, low weight and low 25-OH-vitamine 
D were signifi cantly correlated with BMD of the hip and lumbar spine (table 3.4). Physical acti-
vity and isometric grip strength were also correlated with the BMD of the hip. No relationships 
between other factors and BMD were present. Multivariate regression analysis showed that the 
BMD of the hip and lumbar spine were related to female gender, low weight and low 25-OH-
vitamine D (table 3.5). 
25 (OH) D CONCENTRATION PD VERSUS CONTROLS
 In PD patients 56.2% had a vitamin D defi ciency (mean vitamin D concentration 48.3 nmol/l) com-
pared to 43.2% in the control groups (mean 56.7 nmol/l) (table 3.1). 25(OH)D vitamin D serum 
levels were signifi cantly lower in PD compared to controls (difference = -10.2 nmol/l, p<0.000).
A higher portion of the samples were drawn in the winter to spring (when vitamin D levels are 
lower). The portion of samples drawn in the winter to spring were signifi cantly lower than the 
portion drawn in the summer to fall (43.4 nmol/l vs. 58.8 nmol/l, p<0.00), but these seasonal 
differences had no infl uence on the regression analyses we performed.  
TESTOSTERONE LEVELS
 Regression analysis showed that testosterone levels have no signifi cant relationship with BMD of 
the hip and lumbar spine (Hip: B=0.000, p=0.820; Lumbar spine: B=0.001, p=0.781)
Variable
PD patients
(n=186) 
Control group 
(n=802)
Demographics
Age 64.1 (7.7) 63.3 (8.9)
Men (%) 71% 50%
Weight (kg) 80 (13.1) 76.8 (13.9)
Height (cm) 173.8 (8.6) 170.9 (9.7)
BMI 27.2 (4) 26.2 (3.9)
Vitamin D
25-OH-vitamine D nmol/l 48.3 (20.2) 56.7 (22.9)
25-OH-vitamine D % insufﬁ ciency 56.2% 43.2%
PD characteristics
Disease duration (years) 4.9 (4.2) -
UPDRS III 31 (9.0) -
HY 1 2.1% -
HY 1.5 2.1% -
HY 2 83.2% -
HY 2.5 9.9% -
Physical activity
Level of physical activity
(hours/week)
12.2 (8 to 20.2) -
Sunlight exposure
Regular 
(> 3 time a week going outside)
97% -
 Data refl ect mean (SD), percentage or median (IQ-range). PD=Parkinson’s disease, BMI = Body Mass Index, 
UPDRS III= unifi ed Parkinson’s disease rating scale part III, HY= Hoehn and Yahr stage.
TABLE 3.1 
CHARACTERISTICS OF PATIENTS AND CONTROLS 
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BMD PD patients
Osteoporosis/osteopenia (%) 98 (53.2%)
Normal bone mineral density 88 (46.8%)
BMD total hip g /cm2 0.94 (0.1)
BMD lumbar spine g/cm2 1.06 (0.2)
Z-score hip right 0.25 (0.9)
Z-score hip left 0.22 (0.9)
Z-score lumbar spine 0.72 (1.9)
 Data refl ect mean (sd) or number (percentage %) BMD= Bone Mineral Density, PD=Parkinson’s Disease.
TABLE 3.3
BONE MINERAL DENSITY IN PARKINSON’S DISEASE
Variable
Participants without DEXA 
(n=400)
Participants with DEXA 
(n=186)
Age 65.8 (7.7) 64.8 (7.5)
Gender (%men) 62.5% (n=250) 71% (n=132)
Weight (kg) 81.1 (15.4) 82.0 (13.0)
Height (cm) 171.0 (10.3) 173.8 (8.9)
BMI 27.7 (4.3) 27.2 (4.0)
Disease duration (years) 5.4 (4.7) 4.9 (4.2)
UPDRS III 33.5 (11.0) 31.0 (9.0)
HY 1 1.8% 2.2%
HY 1.5 3.3% 2.2%
HY 2 71.3% 85.5%
HY 2.5 16.3% 10.2%
 Data refl ect mean (SD), percentage or median (IQ-range). PD=Parkinson’s disease, BMI = Body Mass Index, 
UPDRS III= unifi ed Parkinson’s disease rating scale part III, HY= Hoehn and Yahr stage.
TABLE 3.2 
CHARACTERISTICS OF  PATIENTS OF THE PARKFIT STUDY AND SUBGROUP
Variable
BMD Lumbar Spine
B (SE)
BMD Hip total
B (SE)
Age 0.001 (0.002); p=0.551 -0.001 (0.001); p=0.471
Weight 0.006 (0.001); p=0.000 0.004 (0.001); p=0.000
Gender -0.087 (0.033); p=0.009 -0.107 (0.020); p=0.000
25-OH-Vitamin-D 0.002 (0.001); p=0.013 0.001 (0.00); p=0.025
Physical activity -0.013 (0.019); p=0.501 -0.031 (0.012); p=0.010
HY -0.069 (0.056); p=0.216 -0.045 (0.035); p=0.202
TUG 0.004 (0.005); p=0.389 -0.005 (0.003); p=0.139
Isometric grip strength 0.001 (0.001); p=0.152 0.001 (0.000); p=0.001
Levodopa use -0.075 (0.035); p=0.032 -0.014 (0.023); p=0.541
Homocystein -0.001 (0.003); p=0.797 -0.002 (0.002); p=0.265
Testosterone 0.001 (0.003); p=0.781 0.000 (0.002); p=0.820
Variable Regression coefﬁ cients (standard error); p-value
Multivariate analysis BMD
 Lumbar Spine
Multivariate analysis 
BMD Hip total
Gender - 0.09 (0.03); p<0.01* -0.1 (0.02); p<0.00*
Weight 0.01 (0.00); p<0.00** 0.00 (0.00); p<0.00**
25-OH-vitamine D 0.002 (0.001); p=0.01*** 0.001 (0.00); p=0.02***
Physical activity - -0.021 (0.011); p=0.063**
Isometric grip strength - 0.00 (0.001); p=0.604**
TABLE 3.4
UNIVARIATE REGRESSION ANALYSIS BMD LUMBAR SPINE AND HIP TOTAL
TABLE 3.5
MULTIVARIATE REGRESSION ANALYSIS BONE MINERAL DENSITY IN PARKINSON’S DISEASE
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DISCUSSION
 This study showed that over 50% of sedentary patients with early PD had an abnormal BMD. 
Specifically, 41.4% had osteopenia and 11.8% had osteoporosis. These findings are largely 
consistent with previous studies,106 107 110 111 117 118 although the prevalence observed here was lo-
wer compared to other studies, which may be explained by the lower H&Y stages in our cohort. 
Indeed, others have found a greater decrease in BMD in the subgroup of patients with more 
advanced disease.109 A higher prevalence of bone loss in more advanced PD can be explained 
by further diminished activities in daily life,17 greater motor impairment, less sunlight exposure 
due to greater immobility, and continuing weight loss,119 which all result in a further lowering of 
vitamin D levels.
 We should point out that the median Z-scores for bone loss were very close to zero. Therefore, 
the prevalence of osteoporosis in PD may not be more common than in the general popula-
tion.120 However, the absolute prevalence of osteopenia and osteoporosis is very high in this 
sample. Considering the morbidity and mortality related to hip fractures, especially in PD121, 
it is important to be aware of this high prevalence of bone loss even in early stages of the 
disease. Together with the high risk of falls (even in HY stage 2-2.5),31 bone loss is an im-
portant risk factor for fractures in PD patients. In our study, female gender, weight loss and 
low 25-OH-vitamin D levels were identified as significant risk factors associated with a lo-
wer BMD. Female gender and weight loss are well recognized risk factors for bone loss in 
the general population and in patients with PD.53 118 Weight loss is reported frequently 
in PD, also during early stages of the disease, and women with PD are at higher risk.122 123 
 To help to prevent such fractures, preventive strategies are needed, including supplementation of 
the vitamin D deficiency observed here and by others,110 124 125 or by promoting physical activities. 
50 87 126 Preventing or reverting weight loss might also help, as reduced body weight was an addi-
tional risk factor for bone loss. In addition, gait and balance training (and in particular treatment 
strategies aimed at reducing freezing of gait) may help to reduce falls.94 127 128 The high incidence 
of vitamin D deficiency observed in the present study is remarkable. It has been suggested that 
vitamin D deficiency is caused by sunlight deprivation, and low vitamin D levels induce compen-
satory hyperparathyroidism, with further contributes to low BMD in patients with PD.129 However, 
in our study patients experienced sufficient sunlight exposure. Furthermore, our results demon-
strated that PD patients had significant lower levels of 25-OH-vitamin D compared with controls. 
Several studies have confirmed these findings.124 130 131 One study additionally showed that vitamin 
D deficiency was more common in PD compared to patients with Alzheimer disease.124 
 Larger studies remain necessary to further investigate the association between vitamin D and 
bone loss. Pending further evidence, it is important to be alert of vitamin D deficiency in PD and 
its possible effect on BMD and muscle strength. We therefore recommend to consider routine 
measurement of vitamin D in older patients with PD, even in early stages of their disease. 
 The present study is the largest series of PD patients who received bone densitometry measure-
ment. The results of previous studies on the prevalence of osteoporosis are inconsistent and not 
all studies used the same methods of assessment of BMD or the WHO definitions. A major ad-
vantage of our study is that many risk factors associated with bone loss were taken into account. 
 Our study also had several limitations. First, due to its cross-sectional nature, the associations 
observed here cannot be taken as definitive evidence of a causal relationship. Second, the lack 
of a control group for the BMD is a limitation. However, bone mineral density inherently has its 
own controls owing to the method of the statistical measurement of T and Z-scores. As such, a 
mean Z score of 0 would equate to an equivalent age-matched population. Finally, the present 
study was performed in a subgroup of patients selected from the ParkFit trial, an RCT that spe-
cifically selected sedentary PD patients, aiming to promote their levels of physical activity. The 
present findings can therefore not be extrapolated to all PD patients, but may apply only to this 
selected subpopulation.
 We conclude that BMD is often affected, even in early PD. The lower BMD is mainly associated with 
vitamin D deficiency, lower body weight and female gender. These could be clinically important be-
cause of the concomitant risk of fractures in combination with an increased fall risk. We recommend 
that older patients with PD are evaluated for the risk of osteoporosis. Besides classical risk factors, 
vitamin D deficiency and weight loss should addressed. In the case of osteoporosis, treatment with 
bisphosphonates could be considered, in combination with calcium and vitamin D supplementation. 
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CLINICAL EVIDENCE
 Data from observational and case-control studies suggested an independent association 
between PD and lower BMD.52 106 108-111 117 118 140 141 These data were confirmed by three longi-
tudinal studies.52 107 132 We will discuss these three latter studies in more detail next.Two studies 
investigated annual loss of BMD in PD patients. Lörefalt et al. found  significant reductions of 
total body, total hip and femoral neck BMD (3.9% vs 1.2%) in 26 PD patients compared with 
26 controls. Low body weight and low physical activity were risk factors for low BMD, whereas 
rigidity seemed to be protective, possibly by increasing the mechanical load on bones. BMD 
however did not correlate with the severity of PD. An important limitation of this study is the small 
number of  patients en controls.52 
 In the Osteoporotic Fractures in Men Study Fink et al found a significantly (p<0.001) greater 
total hip bone loss of 1.1% compared to only 0,4% in community-dwelling male patients (19 
patients, 4357 controls). However, this study had several limitations: the number of men with PD 
was limited; PD was self-reported; and the number of patients with follow-up date was low.132 
Schneider et al. investigated a cohort of community-dwelling women with and without PD  for 6 
years ( 73 patients, 8032 controls). The authors found no significant difference in baseline BMD 
and in bone loss between the two groups after correcting for confounders. Body weight accoun-
ted for 60% of the difference in BMD. Because of the small number of patients at follow-up the 
authors were unable to assess the association of PD with rate of change in hip BMD. Besides 
the small proportion of patients, this study was also limited by the self-reporting of PD, so the 
duration and severity of the disease could not be taken into account.107
PATHOPHYSIOLOGY
 Several factors may contribute to bone loss in PD (Figure 4.2). Most of these develop in the 
course of PD and affect or reinforce each other.
PHYSICAL ACTIVITY AND EXERCISE
 PD patients are less active compared to healthy controls.87 Bone tissue is sensitive to its me-
chanical environment and is continuously stimulated by muscle contraction and weight-bearing 
movements, and is responding to mechanical stress. Osteocytes and their dendritic connections 
are able to sense fluid flow driven by stresses placed upon bone. In response to these stresses, 
osteocytes produce signaling molecules that stimulate bone remodeling by osteoclasts and 
osteoblasts.142 143 Subnormal mechanical stress as a result of immobilization leads to bone loss, 
with the rate of bone loss being influenced by the duration, intensity, and acuteness of im-
mobilization.144 There are indications that immobility is associated with bone loss in PD, but 
research into this is limited. Only three studies investigated the association between physical 
PD is a common neurodegenerative disease 
characterized by both motor and non-motor 
symptoms. As a result, many PD patients are 
limited in their daily activities.17 Compared to 
age-matched controls, PD patients have a sig-
nificantly increased risk of fractures, mainly of 
the hip. 55 107 132-135 The consequences of such 
hip fractures in PD can be devastating, includ-
ing decreased functionality, length of hospital 
stay, risk of nursing home admission and high 
mortality rates.121 136-138 One explanation for the 
increased fracture risk in people with PD are 
falls, due to postural instability and gait distur-
bances. However, not all fractures in PD – and 
especially vertebral fractures – are related to 
falls.55 107 137 The bone mineral density (BMD) of 
patients with PD is lower compared to healthy 
controls, thus worsening the fracture risk.55 107 
134 139  However, it is unclear how many patients 
with PD experience bone loss. Published esti-
mates of  prevalence of osteoporosis in PD vary 
considerable, and the causes of bone loss, in 
particular, are not well described in the litera-
ture. The aim of this study is to systematically 
review studies reporting bone loss in PD. In this 
review, we focus specifically on the pathophysi-
ological mechanisms of bone loss, and treat-
ment in patients with PD.
LITERATURE SEARCH
 A Medline search was performed for articles published between January 1975 and January 
2011, using the keywords ‘bone mineral density’, ‘bone loss’, ‘BMD’, ‘bone metabolism’, ’frac-
tures’, ‘Parkinson’s disease’, and ‘parkinsonism’. Moreover, reference lists from the included 
studies were checked and author’s names were searched for additional studies. All the articles 
were screened on the basis of their title and abstract. Studies were included if participants had 
PD and the study evaluated risk factors for, or interventions to prevent, bone loss. Only studies 
in which dual energy X-ray absorptiometry of the hip and/or spine was used to measure BMD 
were included. Articles written in languages other than English, expert opinions, case reports, 
and articles of which the full text was not available were excluded. 
SEARCH RESULTS
 This search yielded 403 studies. Twelve papers were considered eligible, using the above menti-
oned criteria (Figure 4.1). Three of those studies were prospective cohort studies, with a follow-
up ranging from 1 to 6 years. The others were observational (mostly case control studies). Men 
and women were equally distributed and mean age varied from 60 to 78 years. Not all studies 
reported disease severity and duration, but when reported UPDRS varied from 25 to 33. Almost 
all patients had a Hoehn & Yahr stage greater than 2, and mean disease duration varied from 
2 to 6.5 years. Most studies did not take all relevant confounders (e.g. vitamin D concentration) 
into account. The characteristics of these studies are summarized in Table 4.1.
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performance/exercise and BMD in PD. The authors Lam and Fink found no association, Lorefält, 
on the other hand, found that the amount of BMD in PD patients was directly correlated to 
physical activity.52 106 108 Data on the association between BMD and the severity of PD are also 
confl icting. Only one prospective study mentioned severity. They found no correlation between 
BMD and severity of PD symptoms. However, besides the small number of patients, none of the 
patients was severely disabled.52 In contrast, results of most observational studies have sugge-
sted a signifi cant association between disease severity and BMD. These studies also consisted of 
small number of patients. Most studies did not account for all potential confounders.109-111 140 141 
Although the evidence is scarce, it seems plausible that physical inactivity, which worsens as the 
disease progress, contributes to bone loss in PD.
FIGURE 4.1
FLOW DIAGRAM OF STUDY SELECTION PROCESS 
Records identified through searching of Medline and 
screened (title, abstract) (n=403) 
Additional record identified from reference list and 
author’s names (n=15) 
Records excluded by screening title and abstract 
(n=359) 
Full text records excluded (n=34): 
Studies did not use DEXA of the spine or hip (n=12) 
Outcome measure was not BMD (n=7) 
Systematic review or meta-analysis (n=5) 
Non-eligible study design (n=10) 
 
Records included in review (n=10) 
Full text records excluded (n=13): 
Studies did not use DEXA of the spine or hip (n=4) 
Outcome measure was not BMD (n=3) 
 
 
Full text records assessed for eligibility (n=44) 
Records included in review (n=2) 
Total number of records included in review (n=12) 
TABLE 4.1
LITERATURE ABOUT BMD AND PD
First Author 
(reference nr)
Year of 
publication
Number of 
patients/ controls
Outcome measure 
(DEXA)
Results
Lam108 2010 108 215 Hip (four subregions), 
lumbar spine and body 
BMD
Female, but not male patients with PD 
have lower hip BMD (p=0.005). After 
multivariate adjustment, the result did 
not reach statistical signifi cance.
Abou-
Raya192
2009 82 68 Lumbar spine and 
femoral neck BMD.
PD patients have signifi cantly lower 
BMD at lumbar spine and femoral 
neck (respectively p=0.005 and 
p=0.001).
Song109 2009 107 100 Lumbar spine and 
femoral neck BMD.
Femoral neck and lumbar spine BMD 
were signifi cantly lower in PD (p<0.00).
Bezza111 2008 52 52 Lumbar spine and dual 
femur BMD
BMD at lumbar spine and hip was 
lower in PD (respectively p<0.001 
and p=0.02).
Fink132 2008 46 5891 Hip BMD Total hip bone loss was greater in men 
with PD (p<0.001).
Schneider107 2008 73 8032 Total hip and femoral 
neck BMD
Total hip BMD was lower in women 
with PD (p<0.01). After multivariate 
adjustment, the result did not reach 
statistical signifi cance.
Kamanli141 2008 28 31 Lumbar spine, proximal 
femur and hand BMD.
In female, but not male, patients hand 
and femoral neck BMD were signifi -
cantly lower (p<0.05).
Lörefalt52 2007 26 26 Hip and total body BMD The BMD was lower at all sites in PD at 
year 1 and 2 compared with controls 
(p<0.05) and decreased during the 
investigated year.
Di Monaco140 2006 28 28 Hip (fi ve subregions) 
BMD
BMD did not differ signifi cantly be-
tween PD patients and controls with 
hip fracture
Wood118 2005 105 - Hip (three subregions) 
and lumbar spine BMD
41.9% of the PD patients had osteopo-
rosis and 34.5% osteopenia.
Fink106 2005 52 5943 Hip (three subregions) 
and lumbar spine BMD
PD was associated with lower BMD at the 
spine (p=0.04) and total hip (p=0.07)
Taggart117 1995 51 51 Hip and lumbar spine 
BMD
Total hip (p=0.014) and femoral neck 
(p<0.004) BMD were decreased in 
PD patients. No signifi cant difference 
was found for the lumbar spine.
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VITAMIN D DEFICIENCY
 Vitamin D has a crucial role in bone metabolism, and a shortage of vitamin D is correlated with an in-
creased risk of falls and fractures.145 Vitamin D defi ciency results in hypocalcemia and compensatory 
hyperparathyroidism, and an excess of parathyroid hormone causes bone resorption by stimulating 
osteoclast activity.144-146 Vitamin D defi ciency is common in PD and may be related to malnutrition, immo-
bility and sunlight deprivation. The prevalence of vitamin D insuffi ciency is signifi cantly higher in patients 
with PD compared to healthy controls or patients with Alzheimer disease, which suggests that there is 
a specifi c association between PD and vitamin D defi ciency.124 147 148
 Vitamin D  has an important role in the human brain. 1,25(OH)2D is synthesized in neurons and mi-
croglia by 1α-hydroxylase. Active vitamin D binds to vitamin D receptors (VDR) and regulates several 
genes involved in cell differentiation, proliferation, and apoptosis. VDR are expressed throughout the 
brain, with the strongest expression of both 1α-hydroxylase and VDR being found in the (presumably 
dopaminergic) neurons of the substantia nigra.149 Matkovits et al showed that dopamine can induce 
VDR-mediated signaling in the absence of active vitamin D.150 This supports the hypothesis that vi-
tamin D has autocrine and paracrine functions in the nervous system. Vitamin D also seems to have 
neuroprotective actions, by inhibiting the synthesis of nitric oxide, by exerting direct antioxidant-like 
effects and anti-ischemic actions, and by modulating cytokine release.151 152 Vitamin D and PD are 
also linked at a gene level. Kim et al found an association between PD and VDR gene polymor-
phisms, using genomic DNA extracted from peripheral blood from patients with PD and controls.153 
Newmark and Newmark even hypothesized that a chronically inadequate vitamin D intake may con-
tribute to the pathogenesis of PD. They suggested that a continuous inadequate intake of vitamin D 
leads to a chronic loss of dopaminergic neurons in the brain.154 A recent longitudinal study supported 
this hypothesis. Knekt et al. investigated a cohort of 3173 men and women free of PD in Finland with 
a follow up of 29 years and concluded that low vitamin D status predicted the development of PD 
(50 cases, 3123 non-cases). However, this study had some weaknesses, such as a small number of 
cases, the single measurement of vitamin D, and the possibility of residual confounders due to the 
fact that risk factors for PD are not well known.155
MUSCLE STRENGTH
 Both vitamin D defi ciency and decreased mobility reduce muscle strength (fi gure 4.2). Muscle 
strength has been negatively associated with BMD in various populations, and bone formation and 
remodeling may be affected by local mechanical signals generated by muscle contraction.156-158 
Environmental infl uences (exercise, nutrition, vitamin D) as well as genetic factors infl uence this 
bone–muscle relationship.130 159 The isokinetic muscle strength of patients with PD is  reduced com-
pared with age-matched controls, even in early disease stages, and declines further with disease 
progression. The specifi c cause of this weakness is not known.160 One study reported lower extremity 
muscle strength (isometric hip fl exion and knee extension) to be associated with hip BMD in wo-
men with PD ( 34 patients, 30 controls), after correcting for several confounders.130 Another study 
investigated the association between lumbar spine BMD and trunk muscle strength and found trunk 
muscle strength to be independently associated with lumbar spine BMD ( 43 patients, 29 controls).131 
Both studies were limited by small sample sizes and possible selection bias. 
LOW BODY WEIGHT
 Several studies have suggested that low body weight is a risk factor for low BMD in PD.52 111 117 
Schneider et al found that weight accounted for 60% of the age-adjusted difference in hip BMD 
in 73 women with PD compared with 8032 controls.107 One explanation is the decreased me-
chanical load. In addition, a lower body fat content is associated with lower estriol production 
in postmenopausal women, leading to a reduced BMD.161 162 Patients with PD are at high risk 
of poor nutrition for several reasons, such as impaired hand-mouth coordination, dysphagia, 
intestinal hypomotility, depression, cognitive defi cits, and side effects of medication. At the same 
time, there is an increased energy requirement due to muscular rigidity and involuntary move-
ments. In addition, malnutrition can lead to low levels of vitamin D, folic acid, and vitamin B12, 
with negative consequences on bone formation and strength.123 163
HYPERHOMOCYSTEINEMIA
 Hyperhomocysteinemia is an independent risk factor for osteoporotic fractures.164-166 The catabo-
lism of homocysteine depends on folic acid, vitamin B12, and vitamin B6, and thus folic acid and 
vitamin B12 defi ciency can cause hyperhomocysteinemia. Homocysteine has a direct effect on 
bone by binding to extracellular collagen, which interferes with the formation of collagen cross-
linking.167 168 In addition, in vitro studies have shown that homocysteine stimulates the differentia-
tion of osteoclasts and induces apoptosis of osteoblasts.169-171 The fi rst mechanism results in poor 
bone quality and the second reduces BMD, both contributing to an increased fracture risk.
FIGURE 4.2
FACTORS INFLUENCING BMD AND BONE STRENGTH IN PD
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 Hyperhomocysteinemia is common in PD and is associated with fracture risk and a low BMD.172-
176 In addition to vitamin B12 and folic acid deficiency, levodopa use may cause hyperho-
mocysteinemia. Levodopa and dopamine are methylated by catechol O-methyltransferase 
(COMT), with S-adenosylhomocysteine as methyl donor, to form S-adenohomocysteine. Since 
S-adenohomocysteine is rapidly converted to homocysteine, levodopa therapy can lead to 
hyperhomocysteinemia. Theoretically, inhibition of COMT should reduce levodopa-induced 
hyperhomocysteinemia, but the literature on this is contradictory. These discrepancies in the 
literature might be related to the different levels of vitamin B12 and folic acid in the included 
patients.177-182 Two studies have shown that supplementation of vitamin B12 and folic acid decre-
ases homocysteine levels in levodopa-treated patients.183 184 Moreover, Lee et al. concluded that 
homocysteine-lowering therapy with folic acid and vitamin B12 prevents bone loss in levodopa-
treated patients.185 Another recent study found that not levodopa use, but decreased levels of 
vitamin B12 and folic acid, cause hyperhomocysteinemia in PD.176 
MANAGEMENT AND TREATMENT
 The paragraphs above indicate that a complex interaction between various factors can con-
tribute to bone loss in patients with PD. Optimal management calls for careful assessment of 
all these factors, followed by tailored treatment where possible. Because scientific evidence 
concerning the treatment of osteoporosis in PD is scarce, we would like to recommend clinicians 
to treat PD patients according to the same principles that apply to non-parkinsonian patients. 
Specific recommendations for treatment include: (a) lifestyle factors & exercise; (b) dietary sup-
plementation; and (c) anti-osteoporotic medication.
 The WHO developed the calculation tool FRAX to evaluate fracture risk of patients based on in-
dividual patient models that integrate clinical risk factors as well as BMD at the femoral neck. 
The risk factors of having ‘PD’ or ‘falls related to PD’ have however, not been quantified 
(sufficiently) in FRAX to give an accurate 10-year probability of fracture in these patient categories. The 
FRAX calculation tool can therefore not be recommended in calculating fracture risk in PD patients.186
LIFESTYLE FACTORS / EXERCISE
 Smoking and alcohol are well known risk factors for osteoporosis, so patients should be advised 
to stop smoking and reduce alcohol consumption. Exercise is recognized as key modifiable 
lifestyle factor that is essential to the prevention and management of osteoporosis. Physical 
activity programs for maintaining BMD are based on a site-specific modifying effect, in addition 
to strengthening muscles and improving balance, thus reducing the overall risk of falls and frac-
tures. The influence of exercise on BMD in PD is not well studied. The ParkFit study is currently 
being conducted. It researches whether a physical activity promotion program can increase 
physical activity levels in sedentary patients with PD.87
DIETARY SUPPLEMENTATION
 Sato et al. performed a randomized, double-blind, placebo-controlled trial of 1α-hydroxyvitamin 
D3 supplementation (1 µg/day) for 18 months in patients with PD (43 patients in both groups). 
After 18 months the treatment group showed a smaller decrease in BMD (1.2% vs 6.7%; p<0.00) 
and a lower risk of non-vertebral fractures (18.6% vs 2.3%; OR 9.8, p=0.003).187
 Lee et al. studied the effect of homocysteine-lowering therapy on preventing bone loss in pa-
tients with PD taking levodopa. Patients were randomly assigned to treatment ( n=14 ) (folate 
5 mg daily, mecobalamin 500 µg three times daily) or no treatment ( n=13 ). Both groups took 
daily oral supplements of calcium (500 mg) and cholecalciferol (1000 IU). Follow-up was 12 
months. The authors found that homocysteine-lowering therapy  resulted in significantly greater 
improvements in BMD at the lumbar spine (4.4%), total femur (2.8%), and femur shaft (2.8%). 
Although this was a small trial and fracture reduction was not taken into account, it is an easy 
therapy with minor side effects.185
ANTI-OSTEOPOROTIC MEDICATION
 Only three studies focused on pharmacological treatment of osteoporosis in PD,  all considering 
bisphosphonates. The role for selective estrogen receptor modulators and strontium ranelate 
has not been evaluated in patients with PD.
 The first study, a 2-year, randomized, double-blind, placebo-controlled trial, studied the ef-
fect of risedronate in men with PD (121 patients in both groups). Risedronate (2.5 mg) and 
ergocalciferol (1000 IU) daily were compared with ergocalciferol (1000 IU) and placebo. BMD 
increased 2.2% in the risedronate group and decreased 2.9% in the placebo group, while 
nine patients in the placebo group and three patients in the risedronate group sustained hip 
fractures. So, risedronate reduced the relative risk of hip fracture by 0.33 (95% CI, 0.09 to 
1.20).188 The same authors reported similar benefits in a study of elderly women with PD al-
located to once weekly 17.5mg risedronate and ergocalciferol compared to ergocalciferol and 
placebo (136 patients in both groups).189 The third study investigated the effect of alendronate 
in a 2-year randomized, double-blind, placebo-controlled trial of elderly women with PD (144 
patients in both groups). Patients were treated daily with alendronate (5 mg) or placebo, and 
both groups received ergocalciferol (1000 IU). BMD increased 1.3% in the intervention group 
and decreased 2.8% in the control group. Aledronate reduces the relative risk of hip fractures 
(14 vs 4 fractures) by 0.29 (95% CI, 0.10-0.85).190 A shortcoming of these studies was that BMD 
measurements were performed at the second metacarpal using computer X-ray densitometry 
and not DEXA at the hip. Nevertheless, they found a decrease in the number of fractures. 
Altogether, bisphosphonates seems to be effective for osteoporosis in PD. No drug interaction 
occur with levodopa or other medications used to treat PD and when a patient  experience dys-
phagia bisphosphonates can be administrated intravenously. 
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CONCLUSION
 Patients with PD have a lower BMD than age-matched controls. This reduced bone mass, in 
combination with frequent falls, explains the increased fracture risk. The BMD reduction in 
PD is multifactorial in origin, involving reduced mobility, vitamin D deficiency, hyperhomo-
cysteinemia (caused by levodopa use, or vitamin B12 or folic acid deficiency), malnutrition/
low body weight, and decreased muscle strength. All these factors are common in PD and act 
synergistically (figure 4.2). It is essential to monitor these factors in order to assess the risk of os-
teoporosis and, consequently, reduce fracture risk. Patients with PD are currently not routinely 
screened for osteoporosis191, yet the high incidence of fractures in these patients, resulting in 
an increased morbidity and mortality, makes careful management necessary. An extensive risk 
assessment should be performed, including medication use, level of immobilization, muscle 
strength, and nutritional status. If a patient has several risk factors, then BMD should be mea-
sured with DEXA. If osteoporosis is present, treatment should be started with bisphosphonates 
and vitamin D supplementation, and an adequate intake of calcium. Osteoporosis in PD has 
not been extensively studied and further research is needed.  Larger and more powerful studies 
should investigate the pathophysiology of osteoporosis in PD and ways to prevent bone loss 
and reduce the incidence of fractures.
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MATERIALS
 The activity monitor that was used in this study (Dynaport AM, Mc Roberts BV, The Hague, The 
Netherlands) is a small (64x62x13) and lightweight (55 g) instrument that measures accelerati-
ons of the lower trunk using tri-axial accelerometers. The sample rate is 100 Hz. Data is stored 
on a SD card. The device is placed in a belt, positioned on the lower back between the poste-
rior superior iliac spines. To study walking distances, the activity monitor was first calibrated by 
walking two trajectories of 10 meter and two of 20 meter before starting the experiment. 
EXPERIMENT A: SHORT AND LINEAR WALKING TRAJECTORY
 For this purpose, patients walked at their preferred speed along a marked linear distance in a 
hallway (ranging between 21 and 27 meters).
EXPERIMENT B:  LONG AND MORE COMPLEX ‘REAL LIFE’ WALKING DISTANCE
 For this purpose, we created a walking trajectory through a public building, composed of five 
segments (figure 5.1A). The length of each segment was measured three times with a measu-
ring wheel. The average served as the reference distance. The total trajectory amounted 1097 
meters. Halfway the walk patients were asked if they were able to walk the whole trajectory. If 
this was not possible, because of exhaustion for instance, the trajectory was shortened to 913 
meters. 74% of the patients walked the whole trajectory. 
DATA-ANALYSIS
 The Dynaport Gait Monitor software (McRoberts, The Hague, The Netherlands) was used for 
data analysis. Walking distance and step length were estimated based on the amplitude of ver-
tical pelvic displacement and leg length, using a simple inverted pendulum model of walking.197
STATISTICS
 The actually measured walking distance was taken as the gold standard.  All analyses were done 
on the log-transformed data, because the logarithmic transformation removed the skewness. 
We then used the normal distribution (on the logarithmic transformed data) to calculate the 
limits of agreement, i.e. the 5th and 95th percentiles of the differences between the methods. 
METHODS
 We conducted two separate experiments. In Experiment A we evaluated the ability of the activity 
monitor to estimate short (maximum distance 27 meters) and simple (straight) walking trajec-
tories. In Experiment B we evaluated the ability to quantify a much longer (maximum distance 
1097 meters) and more complex ‘real life’ walking trajectory (walking in the hospital corridors, 
with curves and path deviations).
SUBJECTS
 In Experiment A, we included 28 PD patients (Table 5.1). In Experiment B we included a sepa-
rate new cohort of 23 PD patients (Table 5.1). All patients were randomly recruited from the 
Parkinson Centre Nijmegen. Inclusion criteria was idiopathic PD. In experiment A, patients had 
to be able to walk a distance of 30 meters. In experiment B, patients had to be able to walk a 
distance of 2000 meters. Exclusion criterion was a relevant gait impairment other than PD.  All 
patients were measured in the ‘ON’ state. Before the experiment the Unified Parkinson’s Disease 
Rating scale (UPDRS) motor score and Hoehn and Yahr stage were obtained by a neurologist. 
Height, body weight and leg length were also measured. All subjects gave written informed 
consent prior to the study, as approved by the local Medical Ethical Committee.
Nearly all patients with PD experience gait prob-
lems, often already in early disease stages, with 
clear worsening as the disease progresses. 
It would be helpful to have a simple and objec-
tive tool to quantify gait, both in the laboratory 
setting and in the patient’s own home environ-
ment. This could facilitate clinical decision mak-
ing, or can be used as outcome measure in clini-
cal trials. It is currently possible to provide very 
detailed assessments in the gait laboratory, for 
example using motion analysis systems. While 
accurate, such evaluations are also expensive, 
and not necessarily reflective of real-life per-
formance. Moreover, the gait laboratory only 
documents walking impairments, but does not 
investigate the subject’s actual walking behavior.
To address these limitations, ambulatory gait 
monitors have been introduced to quantify 
movements of the limbs or trunk during a pro-
longed time in daily life. In healthy subjects, 
ambulatory monitors can record spatiotempo-
ral gait parameters such as stride cycles, num-
bers of left and right steps, step length and 
walking speed over ground walking.193 Later 
work also concentrated on applying activity 
monitors in patients with PD.194-196 However, 
none of these studies evaluated the ability of 
activity monitors to estimate walking distances 
in patients with PD. We therefore evaluated the 
ability of a simple activity monitor (based on 
tri-axial accelerometers) to estimate walking 
distance in PD.
INTRODUCTION  
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RESULTS
 Mean (sd) distance measured with the activity monitor in the subgroups of patients (shortened 
trajectory and whole trajectory) in experiment B were 1037.6m (sd: 189.3) and 1059.04m (sd: 
195.9) (Figure 5.1B). The measured distance of the activity monitor was not signifi cantly different 
between the subgroups (p = 0.819). Analysis of the short and long walking distance did not sug-
gest any relevant systematic errors. We therefore calculated the unadjusted limits of agreement. 
In case of short walking distances the difference between the results and the gold standard was 
smaller than 16%. In case of a longer walking distance the limits of agreements were -43 and 
+41%. The difference between the results and the golden standard did exceed more than 40%. 
The subjects did not experience interference or inconvenience of the body-fi xed instrumentation.
DISCUSSION
 The aim of this study was to evaluate the ability of the Dynaport activity monitor to estimate 
walking distances in PD. Precision of this activity monitor to estimate short walking distances 
was good, as demonstrated by adequate limits of agreement. However, the precision to estimate 
long walking distances was less appropriate, with wide limits of agreement. This means that the 
device can measure a  changed walking distance in evaluative research, but only large changes 
can be detected or large patient groups are needed. This moderate precision limits the use of 
this activity monitor for clinical purposes. This activity monitor might be used as a screening tool, 
to estimate walking distances, but the actual walking distance might be the measured distance 
plus or minus 40%. 
Experiment A Experiment B
N 28 23
Age mean (sd) 65.6 (6.6) 63.8 (9.4)
Gender (male/female) 19/9 17/6
Height (cm) 173 (10.7) 175.1 (9.7)
Body mass (kg) 77 (14.7) 75.8 (12.6)
FOGQ 5.8 (5.7) 6.3 (5.8)
% Freezers 39.3% 34.8%
UPDRS 29.4 (12.5) 27.9 (8.8)
HY 1,5 1 -
HY 2 11 7
HY 2,5 5 4
HY 3 8 6
HY 4 2 -
TABLE 5.1
PATIENT CHARACTERISTICS
FIGURE 5.1
WALKING TRAJECTORY AND WALKED DISTANCE
 Activity monitors are most often used to assess physical activity levels or energy expenditure in el-
derly subjects. For this purpose activity monitors are reliable and valid.193 The use of activity mo-
nitors for long-term monitoring of walking distance is still limited. Besides accelerometry, Global 
Positioning Systems (GPS) seem to be a promising approach. However, there are limitations to 
the use of GPS, because this requires signals from satellites to estimate position. Interference of 
the signals, caused by blockages due to buildings, travel public transport, tunnels or local topo-
graphy, will affect the accuracy of the GPS. Furthermore, there is a limited storage capacity and 
GPS combined with accelerometry is less feasible because subjects have to wear two systems
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ABSTRACT
BACKGROUND
 Patients with PD are physically less active than controls, and autonomic dysfunction may contri-
bute to this sedentary lifestyle. Specifically, an altered cardiovascular response to physical effort 
may restrict physical activities. Here, the cardiovascular responses to a submaximal exercise test 
were assessed in PD patients and controls
METHODS
 546 sedentary PD patients and 29 sedentary healthy controls performed the Åstrand-Rhyming 
submaximal cycle exercise test. The average heart rate was used to estimate maximal oxygen 
consumption (VO2max). Variables that may affect submaximal activity in PD patients, including 
disease severity, fatigue, and level of physical activity in daily life, were recorded.
RESULTS
 Fewer PD patients (46%) completed the submaximal exercise test successfully than the con-
trols (86%). The estimated VO2max of patients with a successful test was 34% lower than the 
controls (p<0.001). Multivariate regression analyses revealed that higher body weight, lower 
systolic blood pressure, lower resting heart rate, and lower maximal workload were associa-
ted with an increased risk of an inadequate heart rate increase during submaximal exercise 
(R2=27%). PD patients with a successful submaximal exercise test had lower estimated VO2max 
values than controls.
CONCLUSION
 Importantly, half of the PD patients had an inadequate heart rate increase during submaximal 
exercise, which was likely caused by cardiac sympathetic denervation leading to autonomic 
dysfunction. PD patients should therefore be screened to identify their limitations in exercise 
performance. Caution should be applied when prescribing beta blockers, as they might limit 
physical activities further.
METHODS 
PARTICIPANTS
 The study population consisted of 586 PD patients participating in the ParkFit study, a rando-
mized controlled trial evaluating the effectiveness of a multifaceted behavioral program to in-
crease physical activity in PD patients87, and 29 age- and gender-matched controls (Table 6.1). 
Patients were recruited from September 2008 through January 2010, and controls were recrui-
ted from January 2011 through June 2011. Eligibility criteria for all participants were as follows: 
(a) age between 40 and 75 years; and (b) a sedentary lifestyle that was defined as <3 times a 
week of vigorous intensity physical activity for <60 minutes or <3 times a week of moderate in-
tensity physical activity for <150 minutes.201 All PD patients were diagnosed in accordance with 
the UK Brain Bank Criteria.3 Exclusion criteria for all participants were as follows: (a) inability to 
complete Dutch questionnaires; (b) severe co-morbidity interfering with daily functions; (c) daily 
institutionalized care; (d) pulmonary disease; and (e) high risk of cardiovascular complications. 
For the PD patients, the following additional exclusion criteria were applied: (a) unclear diag-
nosis (i.e. no gratifying and sustained response to dopaminergic therapy); (b) Mini-Mental State 
Examination score <24; and (c) deep-brain surgery. 
 Each subject provided written informed consent prior to the study, which was approved by the 
local Medical Ethics Committee (CMO Regio Arnhem-Nijmegen). 
INTRODUCTION  
Patients with PD are physically less active 
than controls.17 Several possible factors may 
account for this physically inactive lifestyle. 
Patients with PD develop a range of motor 
symptoms, including gait disturbances and 
balance instability. Furthermore, patients with 
PD develop several non-motor symptoms such 
as depression, apathy, and cognitive dysfunc-
tion. Taken together, these motor and non-
motor symptoms can discourage PD patients 
from becoming physically active.
Here, we tested the hypothesis that autonomic 
dysfunction is be an additional contributing 
factor of physical inactivity in PD. Autonomic 
dysfunction occurs in more than 50% of PD 
patients198 and can affect cardiovascular re-
sponses to physical activity, thereby restricting 
exercise performance.199 200 However, the in-
fluence of autonomic dysfunction on exercise 
in PD has not been investigated extensively. 
To examine whether PD patients have an al-
tered cardiovascular response to submaximal 
activity, we studied changes in heart rate and 
maximal oxygen consumption in sedentary PD 
patients while performing a standardized sub-
maximal exercise test. 
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EXPERIMENTAL PROCEDURES
 Physical fitness was assessed using the Åstrand-Rhyming submaximal exercise test on a stationary 
bicycle.202 The subjects were seated on a model 939E bicycle ergometer (Monark, Vansbro, 
Sweden). The exercise protocol started after a one-minute warm-up stage at 50-watt resistance. 
After warming up, the workload was increased during the first three minutes of the test. During 
the last three minutes, the workload was kept constant in order to achieve a steady-state heart 
rate. The subjects were asked to maintain a cycling rate of 70 rpm, and the total duration of 
the test was six minutes. If the heart rate in the fifth and sixth minutes of the test differed by 
more than five beats per minute, the test was prolonged by one minute in order to achieve a 
steady-state heart rate. This submaximal exercise test was followed by a cooling-down period 
of at least three minutes. All patients were asked to take their dopaminergic medication two 
hours before assessment. 
ASSESSMENTS
 The level of physical activity was measured using a validated interview-based 7-day recall in 
the form of the LAPAQ questionnaire.112 Fatigue was measured using the Fatigue Severity scale 
(FSS).203 In the PD patients, disease stage was scored according to the modified Hoehn and Ya 
hr scale (H&Y)113, and motor function was assessed using the Unified Parkinson s´ Disease Rating 
Scale (UPDRS III, motor examination).204 In addition, clinical characteristics such as disease time 
since diagnosis and daily levodopa equivalent dose were assessed. Blood pressure at rest was 
measured in the right upper arm using an automatic blood pressure device (Microlife, model 
BP3AC1-1). During the submaximal exercise test, heart rate was continuously recorded using a 
Polar Pacer Tester (Polar, Favor, Kempele, Finland). Perceived exertion was recorded at the end 
of the test using the Borg’s 6–20 rating of perceived exertion (RPE) scale in which a score of 6 
indicates ‘light exertion’, and a score of 20 indicates ‘extreme exertion’.205 206
DATA ANALYSIS
 The submaximal exercise test was considered to be successful if it fulfilled the following criteria: 1) 
a steady-state heart rate (i.e. no more than a 5-bpm change in heart rate in the last two minutes 
of the test) and 2) a heart rate >120 bpm in the last two minutes of the test (70-75% of the estima-
ted maximal heart rate207). When the submaximal exercise test met these criteria, physical fitness 
was then estimated using maximal oxygen consumption (VO2max), which was estimated from the 
Åstrand-nomogram using mean steady-state heart rate with corrections for age and gender.202 
STATISTICAL ANALYSIS 
 Differences in VO2max between the PD patients and controls were evaluated using a t-test and 
Chi-squared test. Univariate logistic regression analysis was used to determine the variables that 
were significantly associated with achieving a heart rate >120 bpm in the PD patients during the 
test and included age, gender, resting heart rate, blood pressure, level of daily physical activity, 
fatigue, maximal workload, perceived exertion, UPDRS III motor examination, disease duration, 
and PD-related medication. Logistic multiple stepwise regression analysis was used to determine 
whether the different variables jointly affected the exercise test in PD patients. 
RESULTS 
 Five hundred and forty-five of the original 586 PD patients and 29 controls performed the 
submaximal exercise test; 41 PD patients did not perform the submaximal exercise test due to 
technical problems. Ninety-two (17%) of the patients were excluded from the analyses due to the 
use of beta blockers (Figure 6.1); none of the controls used beta blockers. The characteristics of 
the remaining 453 patients and 29 controls are presented in Table 6.1. 
 Two hundred and forty-one (53%) of the PD patients and four (14%) of the controls had an un-
successful submaximal exercise test. Of these 241 patients and four controls, 53 (22%) patients 
and three controls terminated the submaximal exercise test prematurely due to exhaustion, 57 
patients (24%) did not reach a steady-state heart rate at the end of the test (i.e. had a >5-beat 
per  minute variance), and 131 (54%) patients and one control reached a steady-state heart rate 
during the submaximal exercise test but had an inadequate heart rate increase (<120 bpm). This 
left 212 (46%) patients and 25 (86%) controls with a steady-state heart rate and an adequate 
heart rate increase during submaximal exercise for inclusion in the analysis (Figure 6.1). 
 The estimated VO2max of the PD patients with a successful test was significantly lower than con-
trols (p<0.001) (Table 6.2). Similar results were obtained when the level of daily physical activity 
was included in the analysis as a covariate.
 Next, the 131 PD patients with an unsuccessful submaximal exercise test due to an inadequate 
increase in heart rate were compared with the 212 patients with a successful submaximal exer-
cise test (Table 6.3). With the exceptions of H&Y stage and PD medication, all factors were 
significantly associated with the ability to increase heart rate sufficiently during submaximal exer-
cise. Multiple stepwise regression yielded a model in which higher body weight, lower systolic 
blood pressure, lower resting heart rate, and lower maximal workload were associated with an 
increased risk of an inadequate heart rate increase during submaximal exercise. This model ex-
plained 27% of the variance. No relationship between the factors disease duration, H&Y stage, 
UPDRS III motor examination, and PD medication and the ability to increase heart rate during 
submaximal exercise was found. 
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Variable PD patients 
(N=212)
Controls 
(N=25)
95% CI
Mean heart rate end of test, 
bpm (SD)
135.8 (12.2) 138.6 (11.8) -7.8 to 2.3
Maximal workload, W (SD) 88.0 (27.9) 95.6 (29.9) -19 to 4.5
Perceived exertion (SD) 15.4 (2) 14.1 (1.8) 0.4 to 2.1
VO2max, ml/min/kg (SD) 
Both genders 21.9 (5.4) 33.0(8.5) -13.5 to -8.7
Men 23.1 (5.1) 35.7 (8.7) -15.5 to -9.7
Women 20.1 (5.3) 27.5 (4.3) -11.3 to -3.6
Data refl ect mean (SD). 95% CI = Confi dence interval, PD = Parkinson’s disease, W = Watts, VO2max = maximal 
oxygen consumption, BPM = beats per minute
TABLE 6.2
PERFORMANCE DURING THE ÅSTRAND-RHYMING SUBMAXIMAL EXERCISE TEST
Variable PD patients
(N= 453)
Controls
(N=29)
Age, years (SD) 64 (7.7) 61.5 (10.8)
Men 66% 69%
Weight, kg (SD) 81 (13.9) 80.1 (10)
Height, cm (SD) 172 (10.1) 171 (8.6)
BMI, kg/m2 (SD) 27.3 (4.1) 27.3 (3.1)
H&Y stage, number of patients (%)
1 7 (1.5%) -
1.5 16 (3.5%) -
2 339 (74.8%) -
2.5 68 (15%) -
3 23 (5.1%) -
UPDRS III (SD) 32.7 (10.2) -
Disease duration, years (SD) 5.2 (4.5) -
Level of physical activity (hours/week)
LAPAQ total (inter-quartile range) 13.2 (8.6 – 20.9) 10.2 (5.2 – 12.9)
Data refl ect mean (SD), median (IQ-range) or number (%). PD = Parkinson’s disease, BMI = body mass index, UPDRS 
III = unifi ed Parkinson’s disease rating scale part III. LAPAQ = LASA Physical Activity Questionnaire
TABLE 6.1
CHARACTERISTICS OF PD PATIENTS AND CONTROLS
FIGURE 6.1
OVERVIEW OF THE PARTICIPANTS IN THE PRESENT STUDY
PD patients n=586
Performed submaximal  test 
n=545
Did not perform the test due 
to technical problems n=41
Excluded from analysis:
use of beta blockers n=92
PD Patients n=453
Unsuccessful 
submaximal test 
n=241
Exhaustion n=53
Heart rate <120 n=131 
No steady state n=57
Successful 
submaximal test
n=212
Controls n=29
Controls n=29
Unsuccessful 
submaximal test 
n=4
Exhaustion n=3
Heart rate <120 n=1
Successful 
submaximal test
n=25
Performed submaximal  test 
n=29
promotion of physical activity in parkinson's disease • feasibility and effectiveness
68 69
cardiovascular responses during a submaximal exercise test in patients  with parkinson's disease 0606
DISCUSSION
 We found that only 46% of sedentary PD patients adequately increase their heart rate during 
a submaximal exercise test, whereas nearly all sedentary controls (86%) achieved an adequate 
increase in heart rate during the same test. Moreover, the PD patients who were unable to suc-
cessfully complete the test (i.e. reached a steady-state heart rate but had an inadequate heart 
rate increase) had a lower resting heart rate and lower systolic blood pressure. Finally, we found 
that PD patients who successfully completed the submaximal exercise test had a lower estimated 
VO2max than the controls.
 This is the fi rst study to demonstrate altered cardiovascular responses during submaximal exer-
cise in sedentary PD patients with respect to healthy controls. An abnormal cardiovascular res-
ponse to maximal exercise has been demonstrated previously 63 199 208-211; however, these studies 
focused on heart rate during maximal effort and did not fi nd an altered cardiovascular response 
during submaximal exercise. For example, Werner et al.199 reported that during higher exercise 
intensities, half of the PD patients failed to reach 85% of the age predicted target heart rate, 
but they found no differences between PD patients and controls during submaximal exercise. 
In addition, Reuter et al.210 measured cardiovascular function using a cycle exercise test with a 
ramp protocol and found a less-responsive systolic blood pressure during the exercise test and a 
slightly elevated heart rate in the PD patients during low-intensity exercise.210 Katzel et al. studied 
63 PD patients and found that only 11% of patients achieved a true VO2max on a maximal-effort 
treadmill test.211 Most studies included only a relatively small number of PD patients, thereby 
limiting the robustness (i.e. statistical power) of their results. Because we included a much larger 
number of PD patients (n=586), we were able to detect a signifi cant difference in cardiovascular 
responses compared to healthy controls. 
 The inadequate increase in heart rate during exercise that was observed in this study may have 
been caused by dopaminergic therapy. Dopaminergic therapy can aggravate the impairment of 
the automatic control of the blood pressure and heart rate in PD patients.212  Another explana-
tion of the inadequate increase in heart rate may be cardiac sympathetic denervation that led to 
autonomic dysfunction.213-215 This hypothesis is supported by the lower resting heart rate that was 
associated with an unsuccessful submaximal exercise test. Goldstein et al. reported that many 
PD patients have cardiac sympathetic denervation215, which can be present in the presymtomatic 
phase of PD214 216 and does not seem to either be restricted to severe cases or occur as a late 
consequence of the disease.215 An early onset of cardiac sympathetic denervation might explain 
why the cardiovascular response to the submaximal exercise test was not related to disease 
severity in our study. The lower heart rate and blood pressure at rest that were observed in our 
study may be an additional indication of symptomatic denervation of the heart. 
Variable PD Patients 
HR <120
(N= 131)
PD patients 
HR >120
(N=212)
95% CI
Demographics and disease severity
Age, years (SD) 66.1 (6.8) 61.8 (7.7) 2.7 to 5.9
Men 73.3% 62.7% 0.044
BMI, kg/m2 (SD) 28.1 (3.9) 26.9 (4.1) 0.3 to 2.0
Height, cm (SD) 173.3 (9.7) 172.6 (10.1) -1.5 to 2.9
Weight, kg (SD) 84.5 (15.2) 80.1 (12.9) 1.4 to 7.5
UPDRS III (SD) 33.8 (9.5) 31 (10.3) 0.6 to 5.0
Disease duration, years (SD) 5.7 (4.8) 4.7 (4.2) 0.1 to 2.1
Total LED doses (SD) 523.3 (428.5) 436.5 (363.4) 1.3 to 172
Level of physical activity, hours/
week (inter-quartile range) 
12.5 (7.9 – 18.5) 14 (9.3 – 21) -3.7 to 0.7
Fatigue Severity Scale (SD) 44 (1.5) 3.8 (1.6) 0.2 to 0.9
Test variables
Mean heart rate end of test,
bpm (SD)
106.3 (10.1) 135.8 (12.2) -32 to -27
Maximal workload, W (SD) 78 (24.6) 88 (27.9) -16.2 to -4.5
Perceived exertion (SD) 15.7 (2.2) 15.4 (2) -0.2 to 0.8
Resting heart rate, bpm (SD) 70.7 (11.2) 80.8 (13.2) -12.9 to -7.4
Blood pressure systolic, mmHg 138 143 -8.6 to -0.3
Blood pressure diastolic, mmHg 81 85 -6.6 to -2.0
Data refl ect mean (SD), median (IQ-range) or percentage (%). CI = Confi dence interval, PD = Parkinson’s disease, 
BMI = Body Mass Index, UPDRS III = Unifi ed Parkinson's Disease Rating Scale part III, bpm = beats per minute, W = watts, 
HR = heart rate.
TABLE 6.3
THE GROUPS OF PD PATIENTS WHO DID OR DID NOT REACH A HEART RATE >120 BPM
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 Cardiac sympathetic denervation causes decreased heart rate and cardiac contractibility,213 
which cause decreased cardiac output during exercise and are associated with shortness of 
breath217 and fatigue.218 This can restrict PD patients during the daily activities and might force 
them to lead a more sedentary lifestyle.17 Therefore, in an early disease stage, PD patients 
should be screened for the exercise behavior, and they should be tested to determine whether 
any limitations in their exercise performance are secondary to cardiac sympathetic denervation 
and/or autonomic dysfunction, which could have therapeutic consequences, as PD patients with 
autonomic dysfunction can still exercise but need to be cognizant of their cardiovascular limi-
tations. Importantly, beta blockers should be prescribed with caution in these patients, as beta 
blockers can aggravate the inadequate cardiac response to exercise. 
 Even the PD patients with a successful submaximal exercise test had some autonomic abnor-
malities, as we found a 31% lower estimated VO2max in these patients than in the controls. The 
estimated VO2max values that were observed in our study are similar to the values obtained in 
previous studies of PD patients. However, in these previous studies, no significant difference was 
found between PD patients and controls.63 209 Our study of a much larger cohort of PD patients 
and controls compared to previous studies likely underlies these differences. 
 Changes in the body composition of PD patients may explain the low cardiovascular fitness of 
PD patients. A stooped posture or stiff chest wall muscles can potentially influence aerobic ca-
pacity. This was found in a study of patients with ankylosing spondylitis that showed an associa-
tion between musculoskeletal limitations and restrictive respiratory impairment and significantly 
impaired pulmonary function compared to controls.219
 The estimated VO2max in our PD patients (22 ml/kg/min) indicates poor cardiovascular fitness, 
which may have a considerable influence on daily functions. Using an exercise program, it should 
be possible for PD patients to improve their VO2max. Indeed, several studies have shown that an 
exercise program can both improve physical fitness and ameliorate disease-related symptoms 
such as sleep disturbances, cognitive dysfunction, and functional motor performance.220  
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ABSTRACT
BACKGROUND
 The sedentary lifestyle of patients with PD adversely affects their health. Reversing this lifestyle is 
difficult because of combined physical and cognitive handicaps that are intrinsic to PD. Here, we 
evaluate whether a multifaceted behavioral change program increases physical activities in PD.
METHODS
 We performed a multicenter, randomised controlled trial to increase physical activity levels in 
sedentary PD patients. Patients were randomly assigned to the ParkFit program or a matched ge-
neral physiotherapy intervention. ParkFit is a multifaceted behavioral change program, designed 
specifically to achieve an enduring increase in the level of physical activity program (coaches using 
motivational strategies; ambulatory feedback). Primary endpoint was the level of physical activity, 
measured every six months using a standardized 7-day recall the LAPAQ questionnaire. Secondary 
endpoints included two other measures of physical activity (activity diary; and ambulatory activity 
monitor), quality of life (PDQ-39), and fitness (6-minute walk test).
RESULTS
 586 sedentary patients with idiopathic PD between 40 and 75 years with mild to moderate disease 
severity (Hoehn and Yahr stage ≤3) were randomized; 540 patients (92.3%) completed the prima-
ry outcome. During follow-up, overall time spent on physical activities was comparable between 
both groups (adjusted group difference 7%; 95% CI -3 to 17%; p=0.19). Analyses of three secon-
dary outcomes indicated increased physical activity in ParkFit patients, as suggested by the activity 
diary (difference 30%; p<0.001), the activity monitor (difference 12%; p<0.001), and 6-minute 
walk test (difference 4.8 meters; p=0.05). PDQ-39 did not differ between ParkFit and controls 
(difference -0.9 points; p=0.14). The number of fallers was comparable between ParkFit (62%) 
and controls (67%). 
CONCLUSION 
 The ParkFit behavioral change program did not increase overall physical activity, as measured with 
the LAPAQ. The analysis of the secondary endpoints justifies further work into the possible merits 
of behavioral change programs to increase physical activities in daily life.
METHODS
 The ParkFit trial is a multicenter RCT to increase physical activity levels over the course of two 
years in sedentary PD patients. The study design has been detailed elsewhere.87 
STUDY PARTICIPANTS
 Recruitment ran from September 2008 to January 2010. Patients treated in 32 community 
hospitals were invited to participate. Eligibility criteria were: (a) PD according to UK Brain Bank 
Criteria221; (b) age 40–75 years; (c) sedentary lifestyle, defined as: participation in vigorous-
intensity physical activity <3 times a week, and for <60 minutes in total per week; or participa-
tion in moderate-intensity physical activity <3 times a week, and for <150 minutes in total per 
week233; and (d) Hoehn and Yahr stage ≤3. Exclusion criteria were: (a) MMSE <24; (b) unable to 
complete Dutch questionnaires; (c) co-morbidity that interfered with daily functioning; (d) daily 
institutionalized care; and (e) previous deep brain surgery. The protocol was approved by the 
local ethics committee. Informed consent was obtained before the first assessment.
INTRODUCTION
PD is a common neurodegenerative dis-
ease, characterized by motor symptoms221 
and a wide variety of non-motor symptoms 
like depression or apathy.222 Despite optimal 
medical treatment, PD remains a progressive 
disease that negatively affects quality of life. 
Therefore, allied health interventions are in-
creasingly deployed to treat both the motor 
and non-motor symptoms of PD. The evidence 
to support the merits of these interventions is 
growing, and treatment guidelines (based par-
tially on evidence, and partially on practical 
clinical experience) for several allied health-
care interventions have been developed.10 11 89
In recent years, a number of physiotherapy 
programs have been tested in patients with 
PD.99 100 223-225 Reviews and meta-analyses gen-
erally found evidence to support ‘exercise’ as 
being beneficial with regard to physical func-
tioning, strength, balance and gait speed.25 68 
226-228 However, the physiotherapy programs as 
tested in these studies were apparently insuf-
ficient to achieve an active lifestyle. Indeed, 
because of their combined physical limitations 
and mental changes, many PD patients lead 
a sedentary lifestyle.229 Reversing this lifestyle 
could have generic health benefits, including 
increased survival.19 230 231 Promoting physical 
activity may also improve specific symptoms 
of PD, such as insomnia, depression or consti-
pation.232 Furthermore, rodent work suggests 
that physical activity might counter neurode-
generation in experimental parkinsonism.101 102
An individually tailored, disease-specific training 
program is needed to improve physical activity 
in PD.233 We developed such an intervention (the 
ParkFit program87) based on models of behav-
ioural change98 234 and containing established 
behavioural change techniques.235-237 To evalu-
ate this program, we designed a randomized 
controlled trial (RCT) comparing ParkFit with a 
matched control intervention.87
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STUDY OUTCOMES
 Baseline characteristics
 Disease stage was scored according to the modified Hoehn and Yahr scale. Motor function was 
assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS part III, motor examination).
 
 Primary endpoint 
 Several amendments were made in the initial phase of the study, at a time when recruitment 
was underway for only two months. We here report our final selection of endpoints, as specified 
on ClinicalTrials.gov, in the adapted final research protocol that was accepted by the Ethical 
Committee (CMO) Arnhem Nijmegen and in a recent design article.87 
 Primary endpoint was the LAPAQ Questionnaire, a validated interview-based 7-day recall of 
physical activities. The LAPAQ was highly correlated with a 7-day diary (r = 0.68, P<.001), and 
moderately with a pedometer (r = 0.56, P<.001). 238 LAPAQ asks patients about their daily 
amount of specific activities, allowing for calculation of total time spent on physical activities 
(expressed in hours per week). LAPAQ covers the frequency and duration of the net sum of the 
following activities: walking outdoors, cycling, gardening, light and heavy household activities 
and sport activities.238 Consequently, higher scores on the LAPAQ (in hours per week) indicated 
more time spent on physical activity. LAPAQ was measured at baseline, and after 6, 12, 18 and 
24 months. At baseline, and after 12 and 24 months, LAPAQ was completed during face-to-
face interviews; after six and 18 months, LAPAQ was completed by telephone. We assumed that 
patients would increase their level of physical activity during the first months of the intervention, 
and would then maintain this level. Therefore, the main endpoint was the average of the level 
of physical activity during the entire follow-up period (i.e. average of 6, 12, 18 and 24 months). 
This approach has several advantages. First, it provides a global assessment of the results of the 
intervention. Second, it provides maximal power. As the number of assessments that is taken into 
account increases, so does the power. We did not compare all individual time points (at 6, 12, 
18 and 24 months) separately, because this leads to multiplicity.
 Secondary endpoints 
 We defined four secondary endpoints:87 (1) physical fitness, as measured with the 6-minute walk 
test239 at 12 and 24 months (i.e. average of all measurements); (2) quality of life, as measured 
with the PDQ-39240 at 6, 12, 18 and 24 months (i.e. average of all measurements); (3) physical 
activity, measured subjectively every six months with a 7-day activity diary (i.e. average of all 
measurements);241 and (4) physical activity, measured objectively every six months with an am-
bulatory activity monitor (i.e. average of all measurements).242 
 The diary detailed the frequency and total duration (hours/week) spent on five specific activities: 
walking outdoors for >10 contiguous minutes; moderate-intensity cycling for >10 contiguous 
minutes; high-intensity cycling for >10 contiguous minutes; sport activities; and other strenuous 
activities (e.g. cutting wood). The activity monitor (triaxial accelerometer)242 was worn as a nec-
klace, on the belt or in the pocket. Data were collected during waking hours for 14 days and 
were stored minute by minute for each axis; output was expressed in kilocalories/minute. Only 
completely observed days were included in the analysis.243 The monitor was additionally used 
as feedback-tool by patients allocated to the ParkFit program, using light-emitting diodes that 
reflected the amount of actually delivered daily physical activity. Control patients received no 
feedback of their activity monitor.
 Safety and falls
 Safety was assessed by spontaneous reports of adverse events. Serious adverse events were 
classified as events that caused death, were life-threatening, or necessitated hospital admis-
sion. Falls were monitored monthly with an automated telephone system.244 Information about 
adverse events was additionally collected at each physical assessment.
INTERVENTION  
 After baseline assessment, patients were randomly assigned to either the ParkFit program or a 
matched physiotherapy intervention aimed at safety of movements. The investigators logged 
in on a protected website and entered region, Hoehn & Yahr stage, age, gender and current 
physical activity level of the patients. Based on a minimization algorithm with these factors, the 
treatment was allocated and registered. Before inclusion, patients were informed that the trial 
compared two potentially beneficial interventions. We used ‘active’ names for both interventions 
(‘ParkFit’ and ‘ParkSafe’ program). To ensure blinding, patients were examined by trained asses-
sors who were unaware of group allocation. Patients were instructed not to discuss the nature of 
their physiotherapy with the assessors.
 
 Both interventions were delivered solely by experienced physiotherapists in the Dutch 
ParkinsonNet.245 In total, 154 physiotherapists were trained to deliver both interventions. This 
ascertained that differences in personality or style of the physiotherapists could not bias the re-
sults. All patients were offered an equal maximum number of treatment sessions (35/year). The 
full study protocol has been detailed elsewhere.87
 ParkFit program
 The ParkFit program was designed specifically to achieve a sustained increase in physical activity 
levels, based on theories and models of behavioural change98 234 and on effective behaviou-
ral change techniques.235-237 Important elements were: (a) activity coaches who guided each 
patient towards a more active lifestyle during monthly personal coaching sessions; (b) educa-
tional brochure about the benefits of physical activity and suitable activities for PD patients; (c) 
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identifying and overcoming any perceived barriers to engage in physical activity; (d) systematic 
goal setting, using a health contract and logbook; (e) stimulation to participate in group exerci-
ses; and (f) ambulatory monitor with automated feedback reflecting actually delivered physical 
activities.242 Ambulatory monitor data were uploaded to a personalized website, where both the 
patient and coach could monitor progress. 
 The ParkFit program also included regular physiotherapy sessions. Based on individual disabili-
ties, the therapist and patient jointly formulated individually tailored treatment aims, according 
to the evidence-based guideline of physiotherapy for PD.89
 Control intervention
 The control intervention consisted of a general physiotherapy program aimed at safety of 
movements, according to the evidence-based guideline.89 Patients received an identical bro-
chure as ParkFit patients, but now with information about the benefits of physiotherapy and 
safety of movements. Patients were offered a maximum number of treatment sessions, simi-
lar to the ParkFit program. An active lifestyle was not explicitly stimulated. Treatment aims 
were jointly formulated by therapist and patient, based on perceived individual disabilities. 
STATISTICAL ANALYSIS 
 Main endpoint was the physical activity level during the entire follow-up (6, 12, 18 and 24 months). 
Because the physical activity level was skewed, medians and interquartile ranges were presented, 
and analyses were performed after logarithmic transformation. Differences between both interven-
tions were evaluated using a linear mixed model with random nested factors ‘patient’ and ‘exercise 
group’. Region, Hoehn & Yahr stage, age, gender and current physical activity level of the patients 
were included as covariables. Results were analyzed according to a modified intention-to-treat prin-
ciple, whereby only patients that had no follow-up measurements at all were excluded.
 
 Sample size calculation
 Based on the following power considerations, we aimed to include a total of 700 patients. In 
a small observational study on physical activity in PD, patients scored 45% less on the LAPAQ 
compared to controls (unpublished data). The coefficient of variation was 110%. Based on a dif-
ference of 20% in hours per week (with coefficient of variation of 110%) between both treatment 
arms, the mixed model analysis will have at least 80% power (when the correlation between 
baseline and follow-up measurements is at least 0.50, and when the correlation between the 
various follow-up measurements is at most 0.75). The decision to define a 20% increase based 
on the LAPAQ activity as a clinically relevant difference was a pragmatic choice, because there 
were no earlier intervention studies that aimed to change activity behavior in PD patients. 
Moreover, prior behavioural change studies in other diseases (e.g. heart failure, diabetes and 
COPD) did not include the LAPAQ as an endpoint. In an earlier study by our group 229, we found 
that PD patients were 29% less active compared to controls (as measured with the LAPAQ): pa-
tients spent 12.9 hours per week on physical activity, while controls spent more than 17.5 hours. 
We deemed an increase in physical activity among PD patients of more than four hours unrealis-
tic, and reasoned that an increase of two hours per week (i.e. an increase of about 20%) would 
be feasible. We also considered a 2-hour increase in physical activity to be clinically relevant, for 
the following reasons. A dose-response relation exists between physical activity and cardiovas-
cular disease or premature mortality.246 Significant risk reductions have been observed with 45-
150 minutes/week of brisk walking.247 Additionally, women who walked or exercised vigorously 
for at least 2.5 hours/week had a 30% lower risk of coronary heart disease.247 Conversely, the 
risk of cardiovascular disease was higher among women who spent >12 hours/day lying down 
or sleeping.247 This suggests that a 2-hour increase in physical activities might help to prevent 
cardiovascular disease. The power is based on two sided 95% confidence intervals. We assu-
med that the clustering due to the fact that the intervention was carried out in training groups of 
approximately eight patients leads to an ICC of 0.1. Based on a previous trial of physical therapy 
in PD,245 we expected a drop-out rate of 10%.
RESULTS
BASELINE CHARACTERISTICS
 586 patients were included (Figure 7.1). 299 patients were randomly assigned to the ParkFit 
program, and 287 to the control intervention. Both groups had comparable demographic and 
disease characteristics, although ParkFit patients tended to be less active in daily life (i.e. less 
time spent on physical activity in hours per week, based on LAPAQ) than controls (Table 7.1). 
LOST TO FOLLOW-UP 
 540 of the 586 participants (92.3%) completed the LAPAQ after 24 months. The proportion of 
patients lost to follow-up was comparable for ParkFit (8.7%) and controls (6.7%). Patients lost to 
follow-up were similar to those who completed the assessments, except for a higher age.
COMPLIANCE 
75 of the 586 participants (12.7%) did not complete the two-year intervention (ParkFit n=44, con-
trols n=31). Main reasons were refusal to change from a regular physiotherapist to a ParkinsonNet 
physiotherapist, too much burden, or dissatisfaction with the intervention. Reasons for drop-out 
were similar between both groups. The mean number of annual individual visits to the physio-
therapist did not differ between ParkFit (13.6) and controls (13.0). Patients in both groups were 
satisfied with the intervention and would recommend the intervention to others (73% versus 71%).
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FIGURE 7.1
SCREENING, RANDOMIZATION, AND COMPLETION OF THE PRIMARY OUTCOME MEASURE
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586 underwent randomization 
299 were assigned to the 
ParkFit program 
287 were assigned to the 
control intervention 
1101 were not willing to participate 
1766 were excluded 
No sedentary lifestyle* (n=1263) 
Severe disease** (n=464) 
Not reached by phone (n=30) 
Did not speak Dutch (n=9) 
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12 months assessment 12 months assessment 
18 months assessment 18 months assessment 
 * No sedentary lifestyle = >3 times a week vigorous-intensity physical activity > 60 minutes; or >3 times a week 
moderate-intensity physical activity > 150 minutes; ** Severe disease = H&Y > III; MMSE < 24; severe co-morbi-
dity interfering with daily functioning; use of daily care in an institution; or deep brain stimulation
ParkFit
(n = 299)
Controls
(n = 287)
Demographics & Clinical Characteristics
Age 65.1 (7.9) 65.9 (7.2)
Men 194 (65%) 188 (65%)
BMI 27.4 (4.5) 27.6 (4.0)
Disease duration (years) 5.0 (4.5) 5.5 (4.6)
MMSE 28.1 (1.7) 28.1 (1.7)
Modiﬁ ed Hoehn and Yahr 
1 7 (2.3%) 4 (1.4%)
1.5 7 (2.3%) 10 (3.5%)
2 221 (73.9%) 223 (77.7%)
2.5 48 (16.1%) 36 (12.5%)
3 16 (5.4%) 14 (4.9%)
UPDRS III 33.1 (11.3) 32.3 (9.5)
Daily levodopa equivalent dose (mg) 458 (362) 499 (414)
Level of physical activity 
LAPAQ (hours per week) 12.8 (8.3 - 20.3) 13.8 (8.3 - 23.9)
Data refl ect mean (SD), median (IQ-range) or number (%). BMI = Body Mass Index (kg/m2). MMSE = mini-mental 
state examination. UPDRS III = unifi ed Parkinson’s disease rating scale part III. LAPAQ = LASA Physical Activity 
Questionnaire. 
TABLE 7.1
BASELINE CHARACTERISTICS
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ENDPOINTS
 Primary endpoint
 Compared to baseline, overall time spent in physical activities was comparable between both 
groups (adjusted group difference 7%; 95% confi dence interval (CI) -3 to 17%; p=0.19) (Table 7.2). 
 
 Secondary endpoints
 Both the activity diary and the activity monitor data suggested increased levels of physical ac-
tivity in ParkFit patients (Table 7.3). Additionally, ParkFit patients increased their physical fi tness 
compared to controls (4.8 meters; 95% CI 0.1 to 9.6; p=0.05) (Table 7.3). Quality of life did 
not differ between the groups (-0.9 points; 95% CI -2.1 to 0.3; p=0.14).
 Safety and falls
 Eight patients died during follow-up because of cardiovascular problems, cancer or medical 
complications (ParkFit n=5, controls n=3). These deaths were unrelated to exercise sessions. 
Controls reported eight hip fractures, ParkFit patients two. Frequency and severity of all other 
adverse events were similar in both groups: ParkFit n=221, controls n=242. The number of 
patients with one or more falls was comparable in both groups: 184 (62%) in ParkFit and 191 
(67%) in controls.
LAPAQ total (primary 
analysis)
N ParkFit N Controls Estimated 
difference (CI)*
p
Baseline 299 12.8 (8.3-20.3) 287 13.8 (8.3-23.9)
6 months 285 13.2 (9.2-20.5) 277 14.2 (8.5-22.0)
12 months 281 12.5 (7.2-21.1) 277 12.4 (7.3-17.9)
18 months 277 12.3 (7.0-19.0) 271 12.3 (6.8-19.1)
24 months 273 12.5 (6.3-18.4) 267 12.0 (7.0-18.3)
Estimated difference (CI)* 7% (-3% to 17%) 0.19
Data refl ect median (IQ-range); * estimated relative difference, based on mixed model analysis.
TABLE 7.2
EFFECT OF THE INTERVENTION (IN HOURS PER WEEK) ON THE LEVEL OF PHYSICAL ACTIVITY MEASURED 
WITH THE LASA PHYSICAL ACTIVITY QUESTIONNAIRE (LAPAQ). 
DISCUSSION
 This RCT shows that a multifaceted behavioural change program does not promote overall phy-
sical activities in sedentary PD patients, as measured with the primary outcome (LAPAQ). Two of 
our secondary outcomes focused on other measures of physical activity, and did suggest impro-
vements for patients allocated to the ParkFit program. This was demonstrated both subjectively 
(with activity diaries) and objectively (with an ambulatory activity monitor). Moreover, physical 
fi tness (an indirect refl ection of greater physical activity) increased in ParkFit patients. Quality of 
life did not differ between both study arms. The ParkFit group did not experience more falls. 
N ParkFit N Controls Estimated 
difference (CI)*
p
Activity Diary
Baseline (hrs per week) 297 5.5 (3.1-10.3) 282 6.3 (3.3-10.5)
Median 6 to 24 months 276 7.6 (4.7-12.4) 276 6.9 (4.2-10.8)
Mean change 275 1.3 273 0.5 30% (17% to 45%) <0.001
Activity Monitor 
Baseline (kcal per day) 273 453 (368-618) 269 462 (346-604)
Median 6 to 24 months 269 504 (390-667) 269 440 (355-582)
Mean change 254 38.7 258 -14.2 12% (7% to 16%) <0.001
Quality of Life (PDQ-39)
Baseline 297 26.0 (13.7) 286 26.2 (13.1)
Mean 6 to 24 months 278 26.4 (13.7) 277 27.7 (12.7)
Mean change 278 0.1 276 1.7 -0.9 (-2.1 to 0.3) 0.14
Physical ﬁ tness (6MWT)
Baseline (distance in m) 298 391.6 (87.5) 283 392.9 (84.5)
Mean 12 and 24 months 256 404 (95.1) 256 394.4 (86.5)
Mean change 255 8.4 253 -1.6 4.8 (0.1 to 9.6) 0.05
Data refl ect mean (SD) or median (IQ-range); * estimated (relative) difference, based on analysis of covariance; PDQ-39 
= Parkinson’s Disease Questionnaire. 6MWT = 6-minute walk test.
TABLE 7.3
EFFECT OF THE INTERVENTION ON THE SECONDARY OUTCOME MEASURE
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 The ParkFit study is therefore a negative trial, showing no difference for the primary outcome (LAPAQ 
questionnaire) between both study arms. We selected the LAPAQ as primary outcome because it 
closely reflected the goals of the ParkFit intervention, namely promotion of physical activities. We 
regarded an actual increase in physical activity levels as a necessary intermediate and prerequisite to 
eventually obtain health benefits, including improvements in quality of life. The LAPAQ questionnaire 
is a validated instrument to measure habitual physical activity in large populations.238 248 LAPAQ 
covers a wide range of daily life activities, and we previously demonstrated that PD patients are 29% 
less active compared to controls, as measured with the LAPAQ.229 Our study was powered to defect 
a 20% increase based on the LAPAQ, which would equate to an increase in physical activities of two 
hours per week. The ParkFit program did not achieve this, suggesting that more robust interventions 
are needed to promote physical activities in daily life.
 Our choice for the control intervention might have obscured greater differences on the LAPAQ 
between ParkFit patients and controls. We chose to refer patients in the control arm to a physio-
therapist who aimed to improve the safety of movements, but without emphasizing the volume 
of physical activities. This approach helped to maintain blinding of patients with respect to 
treatment allocation. An additional reason for having a physiotherapy program as control in-
tervention was that abstaining control patients from physiotherapy for two years was considered 
unethical, in light of growing evidence for the effectiveness of specific physiotherapy interven-
tions.68 226-228 Furthermore, the ParkFit study took place in the ‘real world’, and physiotherapy 
in PD is ‘usual care’, not only in the Netherlands (where at least 60% of PD patients receives 
physiotherapy annually)11 but also in the United Kingdom.249
 Although no effect was found on the primary outcome, two of our secondary outcomes did pick 
up an increase in physical activities, as measured both subjectively (activity diary) and objectively 
(activity monitors). Based on the diary, ParkFit patients spent almost 1.5 hour per week extra on 
physical activity, compared to baseline. This differed significantly from controls, who increased 
their level of physical activity by 30 minutes compared to baseline. This amount of increase in 
physical activity, as observed with the diary, is comparable with findings in elderly populations 
and patients with other chronic conditions.158-161 For example, behavioral counseling for elderly 
in primary care yielded a one-hour increase in moderate-intensity physical activity.158 In addition, 
pedometer-based counseling programs increased total physical activity of cardiac patients by al-
most 1.5 hour/week.159 160 Both the LAPAQ and the diary are subjective instruments, but only the 
diary showed increased activity levels. One possible explanation for this discrepancy is the fact 
that the diary merely includes strenuous activities, while the LAPAQ questionnaire reflects the net 
sum of all physical activities (including household activities). Therefore, we cannot exclude that 
a possible increase in (strenuous) outdoor and sport activities for ParkFit patients was offset by a 
concurrent decrease in household activities. The LAPAQ cannot capture such differential effects 
on specific physical activities as it merely measures the net sum of all physical activities. We there-
fore regard our decision to select overall physical activity as primary outcome as a shortcoming 
in the study design, and this aspect should be addressed in future research in this area.
 Objective assessment of physical activity using a tri-axial accelerometer showed an increase in 
physical activities for ParkFit patients, with a 12% increase in time spent to physical activity after 24 
months. Generally, accelerometers underestimate total energy expenditure, because some activi-
ties are difficult to detect. This includes upper body movements, specific activities such as cycling, 
and relatively static movements such as gardening or strength training.68 On the other hand, ac-
celerometers as used in our study can reliably measure activities such as indoor and outdoor wal-
king.88 128 The accelerometers thus measured a different aspect of physical activity as compared 
to the LAPAQ, and this could explain the difference in outcome with the LAPAQ. Compliance with 
use of the accelerometers was good, suggesting it is a feasible surrogate outcome in future studies. 
The two remaining secondary outcomes aimed at finding possible health benefits. Physical fit-
ness showed a small but significant difference in favor of ParkFit, but quality of life did not differ 
between the ParkFit and control intervention. The ParkFit intervention had no major adverse 
effects. We were concerned about possibly increased fall rates, because the amount of physical 
activity is associated with a greater risk of falling.162 However, the ParkFit program was not as-
sociated with more falls or injuries. In fact, controls reported eight hip fractures, while ParkFit 
patients reported only two. However, these numbers are very small, and this finding is coinci-
dental as we did not include hip fractures as primary or secondary outcome. Therefore, further 
research should investigate whether this difference in hip fractures is related to the intervention. 
Another concern included cardiovascular complications, due to more strenuous activities. All 
participants received a sports health assessment prior to participation. We observed two cardio-
vascular deaths in the ParkFit group, but these were unrelated to exercise. Other adverse effects 
were comparable between both groups. Taken together, this suggest that ParkFit was a safe 
intervention, but that the program needs to be adjusted to achieve more substantial increases in 
physical activity that translate into tangible health improvements.
 Our experience with this ParkFit study was a lesson in trial design in this newly emerging field. 
Although the primary outcome was negative, we have shown the possibility of an exercise based 
trial in disabled people. Several features set the ParkFit study apart compared to previous exer-
cise studies: the prolonged follow-up, showing that patients in both arms were able to comply 
with the intervention for two years; the careful matching of treatment intensity between both 
study arms; the large sample size, making the ParkFit trial by far the largest study on physical 
activity in PD and other chronic diseases;68 232 251 252 and the excellent follow-up rate. The fea-
sibility of the study was supported by the ParkinsonNet infrastructure, a nationwide network of 
allied health professionals who are specialized in PD.256 A generic challenge for trials aiming to 
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evaluate the merits of allied health treatment is the lack of expertise among therapists who deli-
ver the trial intervention, creating undesirable variability and insufficient contrast with the control 
arm. Having expert therapists within ParkinsonNet greatly facilitates the delivery of a relatively 
uniform intervention according to treatment guidelines.245 257 As discussed above, our study also 
highlights the challenges of selecting the appropriate outcomes for a complex intervention such 
as a behavioural change program. Physical activity is a complex behavior: it includes sports as 
well as non-sports activities, and it can be characterized by purpose (occupational or leisure), 
type (cycling, fitness or soccer), intensity (light, moderate or vigorous) and duration. Further 
research should focus on comprehensive, valid and reliable instruments to accurately measure 
all these aspects of physical activity behavior. This is a specific challenge in patients with chronic 
diseases as they perform more light and moderate activities that are easily overestimated when 
using questionnaires, and which are difficult to detect with activity monitors. Furthermore, our 
trial revealed new insights in the risk of selection bias. Our participants were on average less 
sedentary compared with patients who declined to participate.87 Hence, those who needed to 
promote their physical activities most refused participation. It therefore remains unclear whether 
the effects found here can be generalized to more sedentary PD patients. We can neither extend 
our findings to patients with severe apathy, severe cognitive impairment or depression, because 
these were excluded. Finally, the ParkFit program was a multifaceted intervention, with coaches 
using behavioural change techniques, ambulatory feedback devices, and peer pressure from 
group exercises. Future work should decide which of these components is most effective, and if 
any component is also effective when used alone.
 We conclude that ParkFit, a multifaceted behavioural change program, does not change the 
overall volume of physical activities in older, sedentary PD patients. However, analysis of the 
secondary outcomes did suggest greater participation in specific elements of physical activity, 
and demonstrated an improved fitness among ParkFit patients. These results for the secondary 
outcomes suggest that it may be worthwhile to replicate a similar behavioural change study, for 
example with the secondary outcomes as primary parameters. Such a trial may also put more 
focus on quality of life and cost aspects.
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ABSTRACT 
BACKGROUND
 We recently completed the ParkFit study, a two-year randomized controlled trial including 586 
sedentary PD patients, that evaluated a multifaceted intervention (ParkFit program) to promote 
physical activity.  Analysis of the secondary outcomes suggested greater participation in specific 
elements of physical activity, and demonstrated an improved fitness among ParkFit patients. 
Therefore, further implementation of the program could now be considered. To facilitate this 
process, we here evaluate the implementation of the ParkFit program.
METHODS 
 The ParkFit program was evaluated in three ways: (a) experiences of patients and physiotherapists, 
as investigated using interviews and questionnaires; (b) factors associated with changed activity 
levels; and (c) subgroup analyses to identify differential effects in subgroups of patients based on 
baseline physical activity level, age, gender, disease severity, disease duration, and mobility.
RESULTS
 The ParkFit program was well received: 73% of patients indicated they would recommend the 
program to other patients, and 90% of physiotherapists indicated they wanted to use the ParkFit 
program in other patients. The program was effective in almost all subgroups. In women, most 
sedentary patients and patients with lower disease severity, the estimated effect size was largest.
CONCLUSION
 We conclude that the ParkFit program was effective in almost all specific subgroups. Therapists 
and patients experienced no major hurdles. This knowledge can be used for further implemen-
tation into everyday clinical practice to revert the sedentary behavior of patients with PD, and 
perhaps other chronic conditions as well.
INTRODUCTION
Patients with PD are less active compared with 
controls, and this physical activity worsens with 
disease progression.17 Reversing sedentary 
lifestyles could have various generic benefits, 
including increased survival230 231 and lower 
risks of chronic diseases as cardiovascular dis-
ease, diabetes, and cancer.19 Promoting physi-
cal activity may also improve specific symp-
toms of PD, such as insomnia, depression, and 
constipation.220 Moreover, rodent work sug-
gests that physical activity may counter neuro-
degeneration in experimental parkinsonism.101 
102 This observation has fueled speculation 
that physical activity might be used to alter the 
course of PD in humans.
Many patients are well aware of these po-
tential benefits, but changing a sedentary 
lifestyle is difficult. Simply knowing about the 
importance of physical activity is not enough 
to initiate and maintain an adequate physical 
activity level on a regular basis, and it proves 
tremendously difficult to give up unhealthy 
behavior.34 Changing one’s lifestyle when 
old or suffering from a chronic disease such 
as PD is even harder due to physical limita-
tions (e.g. gait and balance impairment) and 
mental changes (e.g. depression, apathy and 
cognitive impairment). 
Considerable research has aimed to develop 
tools for clinicians to enable such high-risk 
groups to successfully change their lifestyle. 
Several physical activity promotion programs 
have shown to be effective; these programs 
were based on healthy behavior theories, used 
behavioral change strategies and were indi-
vidually tailored.34 258 Such a specific interven-
tion program that considered the complexity 
of PD and that addressed all possible barriers 
was not available until recently. Therefore, we 
developed the ParkFit program, an individu-
ally tailored and disease-specific program for 
patients with PD. In a multicentre, randomized 
controlled trial including 586 sedentary PD 
patients, the ParkFit program was compared 
with a matched physiotherapy intervention 
according to the evidence based guideline.89 
The ParkFit program was solely delivered by 
experienced physiotherapists who participate 
in the Dutch ParkinsonNet.15 In total, 116 
physiotherapists offered the ParkFit program 
to 299 patients. 
Although the primary analysis of the Park-
Fit trial showed no differences in levels of 
activity, our secondary outcomes showed 
increased physical activity and improved fit-
ness, without causing more falls (van Nimwe-
gen M and Speelman AD et al., BMJ 2012, 
in press)  Stimulated by these findings, further 
implementation of the ParkFit program into 
clinical practice could now be considered. 
To facilitate this potential implementation 
process, we here evaluate the implementa-
tion of the ParkFit program. Specifically, 
our analyses focused on: (a) experiences of 
therapists and patients with the ParkFit pro-
gram; (b) factors associated with changed 
activity levels; and (c) subgroup analyses, to 
identify whether specific subgroups of pa-
tients might benefit less or more from the 
ParkFit program.
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 Activity Monitor
 All patients received a personal ambulatory monitor.260 This triaxial accelerometer was able to 
show the amount of actually delivered daily physical activity using light-emitting diodes. At a 
personalized website, patient and coach could formulate a personal goal based on kilocalories; 
feedback of the monitor was directly related to this personal goal. Since data of the monitor 
were uploaded to this website, patient and coach could monitor the individual progress.261
 Physiotherapy
 The ParkFit program also included regular physiotherapy sessions. Based on individual disabili-
ties, the therapist and patient jointly formulated individually tailored treatment aims, according 
to the evidence-based guideline of physiotherapy for PD.89
IMPLEMENTATION OF THE PARKFIT PROGRAM 
 We took several steps to enable a successful implementation of the ParkFit program. We first 
developed a specific handbook for physiotherapists, including: (a) information about the be-
nefits and risks of physical activity; (b) information about the process of behavioral change; (c) 
specific user-information for the tools included in the ParkFit program (health contract, activity 
monitor); and (d) a scheme including each coaching session, to help therapists through the 
coaching sessions. 
 Second, we developed the educational workbook for patients which included all elements of 
the ParkFit program. This workbook was not only intended to inform patients, but also to guide 
therapists in dealing with all specific elements important for behavioral change. 
 Third, physiotherapists were trained to treat patients in the ParkFit program during three educa-
tional sessions. These sessions covered the following items: (a) models and theories of behavi-
oral change; (b) general strategies to coach people and to help them to overcome barriers; (c) 
techniques to formulate realistic, concrete and individualized goals; and (d) how to cope with 
differences in character between patient and therapist, because this greatly influences behavior. 
The specific elements included in the ParkFit program were also explained, such as use of the 
Activity Monitor, the educational workbook, the logbook and the health contract. 
 During the two-year intervention period, therapists could consult the research team at any time 
for advice. Moreover, the research team contacted therapists every three months by telephone to 
investigate whether they experienced barriers in delivering the ParkFit program.
 Finally, after one year, an evaluation meeting with therapists was scheduled. These meetings aimed 
to refresh the knowledge of the various ParkFit elements and to discuss therapists’ experiences. 
METHODS
THE PARKFIT STUDY
 This study was part of the ParkFit study, a randomized controlled multi-centre trial aiming to in-
crease physical activity levels over a course of two years in sedentary PD patients  (van Nimwegen 
M and Speelman AD et al., BMJ 2012, in press). Patient characteristics were presented in Table 
8.1. Ethical approval has been granted for the study and all patients signed informed consent. 
The full study protocol has been described elsewhere.87 
PARKFIT PROGRAM
 The ParkFit program was specifically designed to achieve a sustained increase in the level of 
physical activity and was based both on theories and models of behavioral change98 234 and on 
behavioral change techniques with proven effectiveness.235 237 259 
 Activity Coach
 Physiotherapists served as personal activity coaches who guided patients towards a more active 
lifestyle during monthly personal coaching sessions. Physiotherapists educated patients about 
the beneficial effects of physical activity and about suitable activities. Additionally, patients were 
stimulated to participate in group exercise to experience beneficial effects of physical activity 
and to receive social support from fellow patients. 
 Education & Health contract
 Patients received an educational workbook covering specific elements to promote a behavioral 
change. This brochure gave information about the benefits of physical activity and the risks of 
a sedentary lifestyle. Furthermore, suitable activities for PD patients, strategies to identify and 
overcome barriers to engage in physical activity, setting goals and recruiting social support were 
covered. The workbook included a health contract, a written agreement between patient and 
physiotherapist to support patients in initiating and maintaining physical activities by formulating 
long term activity goals.237 Additionally, a logbook was included to monitor short term goals. 
Patients received a bi-annual newsletter accentuating the benefits of physical activity.
 Goal setting
 During the coaching sessions patients and physiotherapists formulated activity goals. These 
goals were created in order to obtain the long term goals as formulated in the health contract. 
During the coaching sessions patient and therapists evaluated these goals as well as the expe-
rienced barriers. The formulated activity goals had to be realistic, concrete and individualized 
and had to be formulated in a systematic way. 
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of life (i.e mean of 6, 12, 18 and 24 months) and changes in physical fitness (i.e. mean of 12 
and 24 months) between both interventions. Fixed factors were treatment arm, score at baseline 
(level of physical activity, quality of life or physical fitness), H&Y stage, age and gender.
RESULTS
EXPERIENCES
 Physiotherapists
 Out of 116 therapists, 113 (97%) were interviewed. The mean number of patients treated by each 
therapist was 2.4 (range 1 – 13). Therapists identified patients’ physical limitations (63%), un-
certainty about their abilities and fear of falling (41%), and declined cognition (41%) as the most 
important explanations for their lifestyle.
 Nearly all therapists (96%) felt competent to offer the specific ParkFit intervention. Only 1% of 
therapists believed that their knowledge of behavioral change was not sufficient. Seventy-eight 
percent was able to deliver the program always or very often. Main reasons for not succeeding 
were: patients' co-morbidity, cognitive disturbances, patients’ lack of motivation, and increased 
disease severity. Formulating concrete and smart activity goals was difficult according to the 
therapists; patients’ physical limitations and cognitive decline were the main reasons for difficul-
ties in goal setting. Almost all therapists (96%) considered that their patients were motivated to 
participate in the ParkFit program.
 Ninety-three percent completed the questionnaire at the end of the study. Therapists reported educa-
tion (94%) and the coaching sessions (93%) as the main tools of the ParkFit program (Table 8.2). Most 
therapists (91%) said they would apply the ParkFit program in other patients with a sedentary life-
style; 89% would offer the program to other PD patients. Twenty-one therapists (15%) mentioned 
suggestions to improve the program.
 Patients
 Out of 299 patients, 255 (85%) completed the questionnaire. Almost all patients (90%) re-
ported they perceived benefits due to the intervention. Seventy-three percent would certainly 
recommend the program to other patients with PD, and 21% would consider recommending the 
program. The most popular tool for patients was the Activity Monitor; 83% of patients identified 
this device as a (very) useful instrument (Table 8.2).
FACTORS ASSOCIATED WITH CHANGED ACTIVITY LEVELS
 Lower age, longer disease duration, better mobility, and lower baseline levels of physical activity 
were associated with larger changes in physical activity (Table 8.3). Multiple forward regression 
analysis resulted in a model with two variables: less baseline physical activity, and better mobility 
were associated with larger changes in levels of physical activity (R2=38%) (Table 8.3). 
EVALUATION OF THE PARKFIT PROGRAM
 Experiences 
 Therapists were interviewed by four independent researchers three to six months after the start 
of the intervention. This telephone interview included various aspects related to the ParkFit pro-
gram. Immediately after ending their participation in the trial, therapists and patients were asked 
to complete a self-administered questionnaire with questions regarding patients’ and therapists’ 
opinions about the program. 
 Factors associated with changed activity levels
 In the ParkFit study, the level of physical activity was primary measured with the LAPAQ questi-
onnaire.112 The LAPAQ questionnaire reflects the net sum of ‘outdoor and sport activities’ plus 
‘household activities’. Post hoc analyses of the ParkFit trail showed that a significant and possibly 
relevant increase (24%) in outdoor and sport activities for ParkFit patients was offset by a con-
current decrease in household activities. Here, we indentified variables that could be associated 
with this change in ‘outdoor physical activity’ as measured with the LAPAQ.
 The following variables were evaluated: disease severity (Unified Parkinson’s Disease Rating 
Scale motor part (UPDRS III), Hoehn and Yahr stage (HY)) 114, disease duration (years), quality of 
life (Parkinson’s Disease Questionnaire (PDQ-39))240, mobility (Timed Up and Go test (TUG)),262 
bradykinesia (Nine hole pegboard test, (NHPT)), fatigue (Fatigue Severity Scale (FSS)),203 anxiety 
and depression (Hospitality Anxiety and Depression Scale (HADS))263, physical fitness (6-minute 
walk test (6MWT))239, and levodopa equivalent dose (mg). Moreover, general characteristics as 
body mass index (BMI), gender, age, and marital status were assessed. 
 Subgroup analyses
 In an exploratory setting, the effectiveness of the ParkFit program was evaluated in specific sub-
groups. Subgroups were defined based on baseline physical activity level, age, gender, disease 
severity (UPDRS III), disease duration, and mobility (TUG). For each variable we classified two 
subgroups based on the median of the whole group. 
STATISTICAL ANALYSES
 Descriptive statistics were used to present quantitative data (i.e. means and percentages). 
Univariate linear regression analyses were performed to study associations between the change 
in level of physical activity during the entire follow-up period (i.e. mean of 6, 12, 18 and 24 
months) and the possible variables (assessed at baseline). Variables that contributed significantly 
were included in a forward multivariate linear regression analysis. Because the physical activity 
level was skewed, medians and interquartile ranges were presented, and analyses were perfor-
med after logarithmic transformation. Furthermore, linear regression analyses were performed 
to determine differences in subgroups for changes in level of physical activity, changes in quality 
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Patients
(n=250)
Physiotherapists
(n=108)
Education 77% 94%
Goal setting (short term) 60% 88%
Goal setting (long term) 59% 83%
Coaching sessions 71% 93%
Activity Monitor 83% 75%
Sport sessions 58% 74%
TABLE 8.2
PERCENTAGES OF BOTH PATIENTS AND THERAPISTS WHO CLASSIFIED THE ELEMENTS OF THE PARKFIT 
PROGRAM AS USEFUL
ParkFit
(n = 299)
Controls
(n = 287)
Demographics & Clinical Characteristics
Age 65.1 (7.9) 65.9 (7.2)
Men 194 (65%) 188 (65%)
BMI 27.4 (4.5) 27.6 (4.0)
Disease duration (years) 5.0 (4.5) 5.5 (4.6)
MMSE 28.1 (1.7) 28.1 (1.7)
Modiﬁ ed Hoehn and Yahr 
1 7 (2.3%) 4 (1.4%)
1.5 7 (2.3%) 10 (3.5%)
2 221 (73.9%) 223 (77.7%)
2.5 48 (16.1%) 36 (12.5%)
3 16 (5.4%) 14 (4.9%)
UPDRS III 33.1 (11.3) 32.3 (9.5)
Daily levodopa equivalent dose (mg) 458 (362) 499 (414)
Level of physical activity (hours per week)
LAPAQ total 12.8 ( 8.3 - 20.3) 13.8 (8.3 - 23.9)
LAPAQ outdoor and sport activities 5.7 ( 3.0 - 10.3) 6.0 (3.5 - 10.3)
LAPAQ household activities 5.0 (2.0-10.7) 5.3 (2.0-13.0)
Data refl ect mean (SD), median (IQ-range) or number (%). BMI = Body Mass Index (kg/m2). MMSE = mini-mental state 
examination. UPDRS III = Unifi ed Parkinson’s disease Rating Scale, part III. LAPAQ = LASA Physical Activity Questionnaire
TABLE 8.1
BASELINE CHARACTERISTICS
Univariate regression
(95% CIs)
Multivariate regression 
(95% CIs)
Level of physical activity
LAPAQ outdoor and sport activities -43.8 (-47.3, -40.1)* -44.8 (-48.3, -41.3)
Demographic characteristics
Age -1.6 (-2.7, -0.5)*
Gender (men = 0) -12.7 (-26.7, 3.8)
Partner (no partner = 0) 5.1 (-16.2, 31.9)
BMI 0.0 (-2, 1.9)
Disease characteristics
Modiﬁ ed Hoehn and Yahr -12.5 (-32.4, 13.3)
UPDRS III -0.6 (-1.4, 0.2)
Disease duration (y) 2.0 (0.2, 3.9)*
Daily levodopa equivalent dose (mg) 0.0 (0, 0)
Additional clinical characteristics
6MWT 0.1 (0, 0.2)
TUG -2.5 (-4.9, -0.1)* -4.7 (-6.5, -2.8)
PDQ-39 0.1 (-0.5, 0.7)
NHPT 0.3 (-0.5, 1.1)
FSS -1.1 (-6.3, 4.3)
HADS 0.2 (-1.1, 1.5)
SCOPA night 0.8 (-1.6, 3.3)
SCOPA day 0.4 (-2.1, 2.8)
LAPAQ = LASA Physical Activity Questionnaire. BMI = Body Mass Index (kg/m2). UPDRS III = unifi ed Parkinson’s 
disease rating scale part III. 6MWT = 6-minute walk test. TUG = Timed up and Go test. PDQ-39 = Parkinson’s 
Disease Questionnaire. NHPT = nine hole peg board test. FSS = Fatigue Severity Scale. HADS = Hospital Anxiety 
and Depression Scale.
TABLE 8.3
REGRESSION COEFFICIENTS (%) AND 95% CONFIDENCE INTERVALS FOR UNIVARIATE AND 
MULTIVARIATE ANALYSES BETWEEN THE CHANGE IN PHYSICAL ACTIVITY (LAPAQ OUTDOOR 
AND SPORT ACTIVITIES) AND THE EXPLORATORY FACTORS MEASURED AT BASELINE
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SUBGROUP ANALYSES
 The ParkFit program was effective in changing the level of physical activity in almost all sub-
groups, except for patients younger than 67, patients with lower mobility scores and more phy-
sically active patients at baseline (Table8.4). The estimated difference between ParkFit and 
controls was largest in the most sedentary patients (estimated group difference 34%, 95% 
Confi dence Interval (CI) 10 to 64%), women (40%, CI=10 to 80%), and patients older than 67 
(38%, CI=13 to 68%) (Table 8.4). The ParkFit program was effective in changing physical fi tness 
in different subgroups (Table 8.4). Quality of life changed only in patients with lower disease 
severity (-1.7, CI=-3.4 to -0.05%) (Table 8.4).
DISCUSSION
 We aimed to evaluate the trial experience with the ParkFit program, as a basis to facilitate future 
implementation into clinical practice. Both therapists and patients were positive about the interven-
tion. Almost all therapists wished to use the ParkFit program in other patients, and 73% of patients 
would recommended the program to other patients. Subgroup analyses revealed that the program 
was effective in almost all subgroups. The most sedentary patients, women, patients with lower 
disease severity, shorter disease duration and elderly patients appeared to benefi t relatively most.
 The different elements of the ParkFit program were offered as a ‘total package’ to achieve a 
behavioral change. Since therapists were educated to offer this multifaceted program and we 
evaluated the program likewise, we cannot conclude whether specifi c elements were more or 
less effective. However, the results of the questionnaire gave some insight in the perceived suc-
cess of the various components. Specifi cally, therapists reported education and the coaching 
sessions as main tools of the ParkFit program, while most patients reported the Activity Monitor 
as the most useful tool. Clearly, these three elements deserve optimal attention when delivering 
the ParkFit program in clinical practice. Future work is needed to decide which component is 
most effective in increasing physical activity levels, and if any component of the ParkFit program 
will also be effective when used in isolation. 
 The program had an excellent compliance: 85% of patients in the ParkFit program completed 
the total intervention (van Nimwegen M and Speelman AD et al., BMJ 2012, in press). Our results 
concerning adherence are comparable with previous short-term programs (up to 6 months)93 
126 but remarkably higher compared with previous long-term programs (up to 14 months).264 In 
an exercise program of six months aiming to reduce fall risk in PD, 54% of patients completed 
at least 75% of the sessions.93 Another study of group exercise in PD found an attendance rate 
of 73% during 14 months.264 Several aspects of our program could have contributed to its high 
adherence. First, the individually tailored character of the intervention – with activities that par-
ticipants enjoyed – makes participation more palatable compared with exercise in general.258 
Change in
Physical activity
Change in 
Quality of Life
Change in 
Physical Fitness
All patients 24% (10% to 40%)* -0.9 (-2.1 to 0.3) 4.8 (0.1 to 9.6)*
Subgroups of patients
Age#
< 67 17% (-1% to 38%) -1.0 (-2.6 to 0.6) 6.1 (-7.3 to 19.5)
> 67 38% (13% to 68%)* -0.8 (-2.6 to 1.0) 17.0 (2.6 to 31.4)*
Gender##
Men 19% (3% to 37%)* -0.8 (-2.2 to 0.6) 9.1 (-2.8 to 20.9)
Women 40% (10% to 80%)* -0.6 (-2.7 to 1.6) 12.0 (-4.4 to 28.4)
Disease duration (years)
< 3.75 27% (5% to 54%)* -1.4 (-3.0 to 0.3) 15.9 (2.7 to 29.0)*
> 3.75 23% (3% to 47%)* 0.13 (-1.6 to 1.9) 4.6 (-9.5 to 18.7)
Disease severity (UPDRS III)
< 32 24% (3% to 51%)* -1.7 (-3.4 to -0.05)* 15.0 (1.7 to 28.4)*
> 32 30% (9% to 55%)* -0.2 (-1.9 to 1.6) 7.4 (-6.5 to 21.3)
Mobility (TUG, seconds)
< 9.25 28% (7% to 52%)* -1.2 (-2.8 to 0.4) 10.5 (-0.8 to 21.9)
> 9.25 21% (-0.1% to 46%) -0.3 (-2.2 to 1.5) 9.3 (-6.0 to 24.6)
Baseline physical activity (hours)
< 6 34% (10% to 64%)* -0.2 (-2 to 1.6) 1.0 (-13.5 to 15.5)
> 6 17% (-0.1% to 38%) -1.3 (-2.9 to 0.3) 18.3 (5.5 to 31.0)*
Data refl ect estimated differences and 95% confi dence intervals; analyses were corrected for age, gender, H&Y, 
and baseline level; #without correction for age; ##without correction for gender; *p < 0.05. Physical activity was 
measured with the LASA Physical Activity Questionnaire (LAPAQ); quality of life was measured with the Parkinson’s 
Disease Questionnaire (PDQ-39); physical fi tness was measured with the 6-minute walk test (6MWT). UPDRS III = 
motor part of the Unifi ed Parkinson’s Disease Rating Scale; TUG = Timed up and Go test. 
TABLE 8.4
EFFECT SIZES OF THE PRIMARY AND SECONDARY OUTCOME MEASURES IN ALL PATIENTS AND FOR 
SUBGROUPS OF PATIENTS BETWEEN PARKFIT AND CONTROLS
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Since patient and therapist jointly chose one or more (sport) activities, patients were allowed 
to follow their own wishes, adjusted to the individual situation. Second, the disease-specific 
knowledge of the therapists could explain the high adherence. The intervention was delivered 
solely by experienced physiotherapists participating in the Dutch ParkinsonNet.15 ParkinsonNet 
networks were specifically developed to improve the PD-specific expertise of health professio-
nals, and to increase patient volumes per therapists.15 Probably, due to these specific elements, 
therapists were able to adequately anticipate on perceived barriers of PD patients, and this 
could have improved patients’ adherence. Most patients who withdrew from the intervention 
did so just after baseline inclusion (4.7%). After about six months, another 5% of patients had 
stopped with the program. Apparently, once patients participate and perceive no ‘starting’ pro-
blems, there are hardly no reasons to stop with the intervention. This suggests that the program 
is feasible and achievable for patients. Besides the excellent compliance of patients, almost all 
involved therapists delivered the intervention for two years and completed both the interview and 
the questionnaire. This shows great enthusiasm and interest with the ParkFit program.
 Multivariate regression showed that larger changes in levels of physical activity were associated 
with less baseline physical activity. The major part of the explained variance was explained by 
baseline physical activity. This could be a simple regression to the mean effect, but it could also 
suggest that poor daily participation in exercise is no reason to withhold patients a physical 
activity program such as ParkFit. Furthermore, better mobility was associated with greater in-
creases in physical activity after two years. Moreover, therapists reported that patients without 
comorbidities and cognitive disturbances were more easy to stimulate towards an active lifestyle. 
Therefore, physiotherapists should take poor baseline mobility, physical limitations, baseline 
physical activity levels, and cognitive functioning of patients into account before starting a be-
havioral change program, for example by engaging the immediate caregiver into the program. 
Perhaps, patients should receive treatment (e.g. by increasing dopaminergic medication, or by 
offering physiotherapy strategies such as cueing) prior to participation.
 Subgroup analyses showed significant differences for almost all subgroups between patients in 
the ParkFit program and controls. In the subgroups of women, patients with lower disease seve-
rity and patients with a shorter disease duration, the benefits from the ParkFit program seem to 
greater. However, these results should be interpreted with caution, because the study was not 
set up to compare subgroups and had insufficient power to reliably detect differences. As such, 
the present results serve only as hypothesis-generating, which call for further confirmation in 
new studies. This work could focus on some promising hypotheses that came from our current 
research, suggesting that specific subgroups may benefit more than others. Specifically, further 
research should focus on the effects of ParkFit-like interventions in women, patients with lower 
disease severity and patients with a shorter disease duration.
 The ParkFit program was now offered solely by physiotherapists with PD-specific expertise, which 
likely helped to overcome any barriers imposed by the physical limitations. The question is 
whether adding professionals from other disciplines might help to improve the quality of the 
behavioral change program. One example that came from the interviews was a psychologist, 
who could address the cognitive issues associated with PD, but who also adds specific expertise 
to change behavior. One could also consider adding sport instructors, since they have specific 
knowledge about coaching, counseling, sports and exercise. It will be interesting to examine the 
possible role of such sport instructors within the ParkFit program. For example, we anticipate 
that patients with greater disease severity will require more specific knowledge of a specialized 
physiotherapist, while patients in earlier stages could be coached solely by a sport instructor.
CONCLUSION
 Our analysis of the ParkFit program yielded several suggestions for improvement: 1) improve 
education for therapists with respect to theories about behavioral change; 2) formulate concrete 
and specific examples of exercise goals; and 3) pay more specific attention to patients with co 
morbidities, cognitive dysfunction and a lack of motivation during education. Sedentary beha-
vior is a major public health problem, and physical activity can have various specific benefits for 
patients with PD. We therefore recommend further implementation of this program into everyday 
clinical practice. 
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 This chapter summarizes the main fi ndings of this thesis and focused on the assessment and 
benefi ts of physical activity in PD and how PD patients can increase their level of physical activity 
using a multifaceted behavioral change program. 
CHAPTER 2 
THE BENEFITS AND RISKS OF PHYSICAL ACTIVITY
 The potential benefi ts and risks of increased physical activity in PD were explored in Chapter 
2. This perspective article identifi ed the following 10 potential benefi ts of an active lifestyle in 
PD patients: 1) prevention of cardiovascular complications, 2) slowing or arrest of osteoporosis 
development, 3) improved cognitive function, 4) prevention or treatment of depression, 5) im-
proved sleep, 6) decreased constipation, 7) decreased fatigue, 8) improved functional motor 
performance, 9) improved drug effi cacy, and 10) optimization of the dopaminergic system (pos-
sibly resulting in modifi cation of the disease course). This chapter also concluded that there is 
still a lack of evidence about the benefi ts of exercise in patients with PD. Most evidence for the 
benefi cial effects of exercise is on cardiovascular mortality and morbidity, cognitive dysfunction 
and mood. The best available evidence that supports the avoidance of a sedentary lifestyle is 
based on studies in healthy individuals and in patients with other neurodegenerative diseases. 
Besides the benefi ts of exercise, there could be an increased risk of falls, fall-related fractures, 
and an increased risk of cardiovascular complications.
CHAPTER 3 
PREVALENCE AND RISK FACTORS OF OSTEOPOROSIS 
 In Chapter 3, one specifi c health benefi t of an active lifestyle was described, which was the 
positive effect on bone mass. Bone loss is regarded as more common in PD than in the general 
population. Several factors may be involved in the development of bone loss. Moreover, osteo-
porosis is an important risk factor for fractures. In Chapter 3, the prevalence of osteoporosis 
in sedentary PD patients was investigated. Furthermore, the possible risk factors that are as-
sociated with bone loss in sedentary patients were studied in 191 PD patients in an early stage 
of the disease (Hoehn and Yahr stage 1 to 2.5). The results demonstrated that the prevalence 
of osteoporosis and osteopenia was 53.2% in patients with an early stage of PD. These results 
were consistent with previous studies about osteoporosis in PD.  Female gender, weight loss and 
 Compelling theoretical reasons support the importance of avoiding a sedentary lifestyle and 
promoting physical activity for patients with, or at risk of developing, PD. However, there is still 
a lack of adequate knowledge about the benefi ts of exercise in patients with PD.
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low vitamin D levels were identifi ed as signifi cant risk factors for decreased bone mineral density. 
Furthermore, vitamin D concentrations were signifi cant lower in comparison with sex and age-
matched controls without PD.
CHAPTER 4
PATHOPHYSIOLOGY AND TREATMENT OF OSTEOPOROSIS
 In this chapter, the pathophysiological mechanisms of bone loss and treatment of osteoporo-
sis were described by reviewing the existing literature. PD patients have a lower bone mineral 
density  compared to age-matched controls. PD patients also have a high risk of falls and 
– consequently – of sustaining osteoporotic fractures. The reduction of bone mineral density 
is multifactorial in origin, and includes reduced mobility, vitamin D defi ciency, hyperhomocys-
teinemia (caused by use of levodopa), vitamin B12 or folic acid defi ciency, malnutrition or low 
body weight, and decreased muscle strength. A few studies demonstrated that treatment with 
bisphosphonates, vitamin D and calcium can increase the bone mineral density in PD patients. 
Screening for osteoporosis should be considered in PD patients more often and therapeutic 
interventions should be initiated for those patients with proven osteoporosis. An appropriate 
treatment of osteoporosis could reduce the risk of fractures in PD patients, but the (cost-)effec-
tiveness of this approach remains to be examined.  
CHAPTER 5 
AMBULATORY MONITORING
 The assessment of physical activity in daily life is complex. Several methods have been proposed 
to assess physical activity levels or energy expenditure including ambulatory monitors. The use 
of activity monitors for long-term monitoring of walking distance is still limited. To evaluate 
whether an ambulatory monitor could estimate walking distance in PD patients, a simple acti-
vity monitor (Dynaport activity monitor) was validated in PD patients in Chapter 5.  This device 
 Over 50% of sedentary PD patients has an abnormal bone mineral density. Female gender, 
weight loss and low vitamin D levels were identifi ed as risk factors for decreased bone mineral 
density in PD. 
 Reduced bone mineral density in PD is multifactorial in origin, including reduced mobility, vita-
min D defi ciency, hyperhomocysteinemia, vitamin B12 or folic acid defi ciency, malnutrition or 
low body weight, and decreased muscle strength. 
measures accelerations of the lower trunk using tri-axial accelerometers and is placed in a belt 
positioned on the lower back between the posterior superior iliac spines. The results demonstra-
ted that the precision of the activity monitor to estimate short walking distance (ranging between 
21 and 27 meters) was good. However, the precision to estimate long walking distances (up to 
1097 meters) was less adequate, with a wide range of agreement (-43% to 41%). The use of this 
monitor for clinical purposes is therefore limited. If this monitor is used as a screening tool, the 
actual walking distance might be the measured distance plus or minus 40%. 
CHAPTER 6 
CARDIOVASCULAR RESPONSES IN PD
 Patients with PD are physically less active than controls. Autonomic dysfunction may contribute 
to this sedentary lifestyle. Specifi cally, an altered cardiovascular response to physical effort may 
limit physical activities. Therefore, in Chapter 6 the cardiovascular responses  to a submaximal 
exercise test in sedentary PD patients and sedentary controls were assessed. The study demon-
strated that PD patients had a lower estimated VO2max compared to controls (22 ml/min/kg 
versus 33 ml/min/kg). Moreover, more than half of the sedentary PD patients were unable to 
adequately increase their heart rate during a submaximal exercise test while almost all controls 
had an adequate heart rate increase. This inadequate increase in heart rate during exercise may 
be caused cardiac sympathetic denervation leading to autonomic dysfunction. The lower resting 
heart rate and lower systolic blood pressure observed in those patients may be an additional 
indication for this symptomatic denervation of the heart.
 Half of the PD patients have an inadequate heart rate increase during submaximal exercise, 
most likely caused by cardiac sympathetic denervation leading to autonomic dysfunction. This 
knowledge should be used when interpreting the outcome of exercise tests to screen the suitabi-
lity of candidates for exercise interventions.
 The accuracy of ambulatory activity monitoring (using tri-axial accelerometers mounted on the 
lower back) for long walking distances is insuffi ciently adequate. Therefore, the use of this type 
of ambulatory monitor for this clinical purpose is limited.
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CHAPTER 7
PROMOTION OF PHYSICAL ACTIVITY
 The evidence for the possible positive effects of exercise on several health outcomes indicates 
that an active lifestyle in PD patients could be benefi cial. The sedentary lifestyle observed in pa-
tients with PD can be explained by physical limitations and mental changes, warranting an indi-
vidually tailored, disease-specifi c  physical activity intervention. Chapter 7 describes the ParkFit 
trial, a multicentre, randomized controlled trial in which a multifaceted, behavioral program, 
the ParkFit program, was compared with a matched general physiotherapy intervention. The 
ParkFit program was designed to achieve a sustained increase in the level of physical activity. 
The intervention was based on theories and models of behavioral change, and on widely used 
behavioral change techniques with proven effectiveness. Both groups were compared for the 
change in physical activity over a course of two years (primary outcome LASA physical activity 
questionnaire (LAPAQ), secondary outcomes of physical activity were a diary and accelerome-
ter). Secondarily the infl uence of a changed lifestyle on the number of falls, quality of life (PDQ-
39) and physical fi tness (six minute walk test) was investigated. We included 586 patients, 299 
in the ParkFit group and 289 in the control group. 
 The results showed that the overall time spent in physical activities was comparable between 
the two groups (difference 7%; confi dence interval, -3 to 17%; p=0.19). Three of our secon-
dary outcomes indicated greater physical activity in patients allocated to the ParkFit program. 
This was demonstrated both subjectively (with activity diaries, difference 30%; p<0.001) and 
objectively (with an ambulatory activity monitor, difference 12%; p<0.001). Moreover, physical 
fi tness increased in ParkFit patients, but not in controls (difference 4.8 meters; p=0.05). Quality 
of life did not differ between ParkFit and controls (difference -0.9 points; p=0.14). The number 
of patients with one or more falls was comparable in both groups: 184 (62%) in ParkFit and 191 
(67%) in controls. 
 Our study showed that the ParkFit behavioural change program did not increase overall physi-
cal activity, as measured with the LAPAQ. Analysis of the secondary endpoints justifi es further 
work into the possible merits of behavioural change programs to increase physical activities in 
daily life. The ParkFit program improved fi tness over a 2-year period, without causing more falls. 
CHAPTER 8 
EVALUATION OF THE BEHAVIORAL CHANGE PROGRAM
 The ParkFit program improved physical activities in sedentary PD patients based on positive 
fi ndings of the secondary outcomes of the ParkFit study (Chapter 7), so implementation in cli-
nical practice seems justifi ed. In Chapter 8, we evaluated elements that are relevant for the 
future implementation of this program; specifi cally, we assessed the following three elements: 1) 
experiences of patients and physiotherapists (investigated using interviews and questionnaires); 
2) factors associated with changed physical activity level; and 3) exploratory subgroup analyses 
to identify differential effects in subgroups of patients based on baseline physical activity level, 
age, gender, disease severity, disease duration, and mobility. 
 Data of 255 (85%) patients and 116 (97%) physiotherapists were collected. Both patients and 
therapists were positive about the intervention. Almost all therapist (90%) wanted to use the 
ParkFit program in other patients and 73% of patients would recommend the program to other 
patients. No major hurdles were reported for further implementation. The most important sug-
gestions included a need for (more) education about coaching and behavioral change tech-
niques, and (more) advice about increasing physical activity in specifi c groups of patients (i.e. 
patients with e.g. co-morbidities). 
 Less baseline physical activity and better mobility were associated with larger changes in physi-
cal activity over two years (R2=48%). Exploratory subgroup analyses revealed that the program 
was effective in almost all subgroups. In women, most sedentary patients, and patients with 
lower disease severity, the estimated size was largest.
 The ParkFit program was effective in almost all specifi c subgroups. Therapists and patients ex-
perienced no major hurdles for further implementation. This knowledge can be used for further 
implementation into everyday clinical practice.
10GENERAL DISCUSSION 
AND FUTURE 
PERSPECTIVES
CHAPTER
promotion of physical activity in parkinson's disease • feasibility and effectiveness
112 113
general discussion and future perspectives 1010
 Several issues related to physical activity and exercise in PD have been answered by the studies 
described in this thesis. Below, these results are discussed and placed into a broader context. 
It is clear that there are still many areas of uncertainty that require further research, and some 
suggestions for this research agenda are also given below. 
IS PHYSICAL ACTIVITY EFFECTIVE FOR PD PATIENTS?
 Although the number of studies on exercise or physical activity increases, there is still a lack of 
evidence about the benefits of exercise in patients with PD, as described in Chapter 2. The most 
recent exercise studies provided some evidence in support of exercise programs in PD. A six 
week treadmill intervention in 20 patients with PD showed improvements in fatigue and quality 
of life, but not in walking capacity, as compared to a control group (usual care with advice to 
maintain current levels of physical activity).126 Executive function improved in a group of 19 PD 
patients directly after 30 minutes passive leg cycling.265 Furthermore, a review of forced exercise 
in animal models and preliminary data on humans with PD has become available, underscoring 
the potential of forced exercise to influence cognition, metabolism, and, potentially, the progres-
sion of neurodegenerative disease.266 
 In general elderly populations, physical activity and exercise are associated with improved bone 
health.56 The effect of exercise on bone mass in patients with PD has not yet been studied 
(Chapter 2 and 4). There is an indication for a complex interaction between various factors 
that can contribute to bone loss in PD. Optimal management of osteoporosis calls for an ex-
tensive risk assessment of all of these factors, including medication use, level of immobilization, 
muscle strength and nutritional status. Furthermore,  the high incidence of vitamin D deficiency 
is particularly interesting (Chapter 3). Until now, the influence of vitamin D deficiency on the 
pathogenesis of PD or the possibility that PD itself leads to vitamin D deficiency is not clearly 
understood. However, it is important to be aware of vitamin D deficiency in PD patients, because 
of the possible effects on bone mineral density and muscle strength. Therefore, pending further 
evidence, it would appear prudent to perform regular measurements of vitamin D in older PD 
patients, starting early on in the course of their disease. Treatment of osteoporosis should be 
similar as for non-parkinsonian patients with osteoporosis and osteopenia and should start 
with bisphosphonates, vitamin D and an adequate intake of calcium.185 187-189 Furthermore, the 
general benefits of physical activity on bone loss in healthy adults can also be expected in PD 
patients. The question is if the high-impact exercises, that are effective in adults in combination 
with weight-bearing exercises57, are also suitable for PD patients because of their high risk of 
falling.31 This now needs to be taken to the test.
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 The aim of the ParkFit study (Chapter 7) was to increase the level of physical activity in sedentary 
PD patients. Overall time spent on physical activities (measured with the LAPAQ) was compara-
ble between patients in the ParkFit program and patients allocated to the control intervention. 
The LAPAQ yields a total sum score for outdoor and household activities, more detailed post 
hoc analyses of the nature of the physical activities showed that ParkFit patients significantly 
increased their outdoor activities (difference 24%; confidence interval 10 to 40%; p<0.001), 
while they reduced their household activities (difference 16%; confidence interval -27 to -3%; 
p=0.02). As a result, the net volume of indoor and outdoor activities was not significantly dif-
ferent between both groups. The question is whether PD patients who increased their outdoor 
activities, actually reduced their household activities. Several aspects could explain this observa-
tion. First, the time spent on household activities was really reduced in ParkFit patients because 
they spent more time outdoors. Alternatively, it is possible that patients who became more active 
outdoors no longer regarded household activities as physical activities, leading to underreport. 
Regardless, ParkFit patients did increase their outdoor activities, and this was a welcome finding 
as outdoor activities are likely associated with greater aerobic challenges. 
 Furthermore, in the ParkFit study the relationship between physical activity and specific health 
benefits was investigated in a post hoc analysis. Small but statically significant correlations were 
found between the change in level of physical activity and changes in mobility, quality of life, 
and disease severity: the subgroup of patients with the greatest increase in physical activity also 
showed better quality of life, lower disease severity scores and relatively greater mobility. The 
observed increase in outdoor activities and sports was 24%, but in terms of health benefits only 
physical fitness significantly increased. These findings support the hypothesis that physical acti-
vity is accompanied by health benefits. However, the results have to be interpreted with caution 
since the direction of these relations is unclear; for example, patients with only minimal changes 
in disease severity could have been able to increase physical activity more easily. 
 The lack of evidence for health outcomes in the ParkFit study could possibly be explained by a 
low intensity of activities. Patients become more active, but probably the intensity of the activities 
is not sufficient for health benefits to be picked up. There is evidence that aerobic physical activi-
ties which improve cardiorespiratory fitness are beneficial for cognitive function in healthy older 
adults.51 The question is whether PD patients can continue to participate in intensive aerobic phy-
sical activities for prolonged periods of time, and whether such greater efforts will translate into 
tangible clinical effects. Furthermore, if intensive aerobic activities are required to examine these 
effects, PD patients must be able to increase their heart rate during physical effort. The question is 
whether this is suitable for every PD patient, in light of their inadequate heart rate increase during 
submaximal exercise as described in Chapter 6. Another concern is that PD patients become only 
partially more physically active (by example, participating in fitness classes for two hours a week), 
but during the rest of the time such patients may still spend a lot of time being sedentary, which in 
turn is related to all-cause cardiovascular disease and mortality.267 268 The influence of single exer-
cise sessions or divided exercise sessions on health outcomes needs to be further investigated. 
THE ASSESSMENT OF PHYSICAL ACTIVITY
 The assessment of physical activity in daily life is complex. Several methods have been pro-
posed to assess physical activity levels or energy expenditure including questionnaires, diaries 
and ambulatory monitors. In the ParkFit study, we selected a physical activity questionnaire 
(LAPAQ) as our primary outcome measure (Chapter 7). This questionnaire is a validated in-
strument to measure habitual physical activity112 and as such, it was closely related to the goals 
of the ParkFit intervention, namely promotion of physical activities.112 A disadvantage of physi-
cal activity questionnaires could be the overestimation of activities or delivery of socially desi-
rable answers by the respondents.269 People tend to over-report physical activity, for example 
household activities, and to underestimate sedentary activities like watching television.270 271 
The ParkFit study showed that a multifaceted behavioural change program does not promote 
overall physical activities in sedentary PD patients, as measured with LAPAQ. However, two 
of our secondary outcomes did suggest greater physical activity in patients allocated to the 
ParkFit program. This was demonstrated both subjectively (with activity diaries) and objectively 
(with an ambulatory activity monitor). Both the LAPAQ and the diary are subjective instru-
ments, but only the diary showed increased activity levels. One possible explanation for this 
discrepancy is the fact that the diary merely includes strenuous activities, while the LAPAQ 
questionnaire reflects the net sum of all physical activities (including household activities). 
 However, it was reassuring to see that the post hoc findings from our primary outcome (na-
mely an increased time spent on outdoor and sport activities, with a 24% difference in favor 
of ParkFit patients compared to controls) were confirmed by these two secondary outcome 
measures, both in terms of direction of the effect (showing benefits for the ParkFit group) 
and magnitude of the effect (expressed as a percentage difference). Specifically, the activity 
monitor showed a 12% difference in favor of ParkFit, and the activity diary showed a 30% dif-
ference in favor of ParkFit. 
 Overall, this study shows (again) that physical activity is a complex behavior: it includes sports 
as well as non-sports activities and it can be characterized by purpose (occupational or lei-
sure), type (cycling, fitness or soccer), intensity (light, moderate or vigorous) and duration. 
Taken together, the outcomes of the ParkFit study offered converging evidence for a beneficial 
effect of the ParkFit program on (outdoor) physical activities, but only if the LAPAQ is divided 
into outdoor and sport activities and household activities. Further research should focus on 
comprehensive, valid and reliable instruments to accurately measure all of the aspects of 
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physical activity behavior, specifically in patients with chronic diseases as they perform more 
light and moderate activities which are easy to overestimate when using questionnaires and 
difficult to detect with activity monitors.
 Activity monitoring has potential as a practical tool to study activity levels in older patients.272 
Many different types of ambulatory monitors are available.273 In Chapter 5, a simple activity 
monitor was validated for use as a tool to assess walking distances in PD patients. Specifically, 
this ambulatory monitor measures accelerations of the lower trunk using tri-axial accelerometers 
and is placed in a belt positioned on the lower back between the posterior superior iliac spines. 
The results showed that the ambulatory monitor can be used to measure short walking distances 
(up to 27 meters), but the tool had a less accurate precision for longer walking distances (up to 
1097 meters). Besides accelerometry, Global Positioning Systems (GPS) seem to be a promising 
approach for understanding physical activity behavior at the population level.274 Future research 
is needed on the use of ambulatory monitors in specific groups, such as patients with PD who 
experience specific types of gait problems (for example, hypokinetic gait, freezing of gait, or 
dyskinetic gait induced by medication). Furthermore, different types of activities like cycling or 
more static activities (like weight-bearing exercises or household activities like washing windows) 
should ideally be assessed using such ambulatory monitors. 
 In case of aerobic training, data are often expressed as a percentage of maximal oxygen intake. 
In Chapter 6, the cardiovascular responses of PD patients to a submaximal exercise test and the 
estimated VO2 max were compared to controls. More than half of the PD patients were unable 
to adequately increase their heart rate, which may be caused by cardiac sympathetic denerva-
tion leading to autonomic dysfunction. This cardiac sympathetic denervation may have several 
consequences. It leads to a lower heart rate and cardiac contractibility,213 which causes a lower 
cardiac output during exercise, which is associated with shortness of breath217 and fatigue.218 
This may limit PD patients during daily activities and might force them to lead a more sedentary 
lifestyle.17 In an early disease stage, PD patients should therefore be screened for exercise beha-
vior, and be examined to identify whether any limitations in exercise performance are secondary 
to cardiac sympathetic denervation and autonomic dysfunction. Further research should focus 
on a reliable submaximal screening tool to asses cardiorespiratory fitness in PD patients with 
autonomic dysfunction in clinical practice. Furthermore, the observed cardiac sympathetic de-
nervation and autonomic dysfunction could have therapeutic consequences, as the use of beta 
blockers may aggravate the inadequate heart rate response to exercise. Beta blockers should 
therefore be prescribed with caution, certainly when patients are referred for exercise programs. 
IS PHYSICAL ACTIVITY PROMOTION FEASIBLE 
IN PD PATIENTS? 
 The first reason to recommend the ParkFit program to PD patients is that the ParkFit study 
(Chapter 7) showed that older sedentary patients with a chronic disease like PD can increase 
their level of physical activity based on the secondary outcomes (Chapter 7), and that this could 
increase physical fitness without causing more falls. Although the evidence for health benefits 
was weak, there is substantial evidence that older adults who are less active than recommended 
by guidelines can achieve health benefits.201 Our participants were on average less sedentary in 
comparison with patients who were not willing to participate,87 so those people that may have 
benefited most from exercise declined to participate. Future work should focus on patients that 
are more sedentary than our population. Second, the experiences of patients and therapists in 
the ParkFit program were encouraging (Chapter 8). Specifically, almost all therapists said they 
would use the ParkFit program in other patients after the trial, and reported no major hurdles 
for further implementation. Ninety percent of the patients reported benefits due to the interven-
tion and have recommend the program to other patients. Furthermore, the program showed 
an excellent attendance rate: 85% of the patients in the ParkFit program completed the total 
intervention, despite the long trial duration of two years. Therefore, we recommend further im-
plementation of the ParkFit program. 
 In general, age, gender, health status, and fear of falling are associated with exercise behavior.96  
In PD patients, two studies investigated the determinants of physical activity.17 275 Self-efficacy 
was associated with regular exercise in community-dwelling PD patients.275 Furthermore, physi-
cal inactivity was associated with worse walking performance, more disability in daily life, and 
greater disease severity.17 In Chapter 8, we tried to identify factors associated with increased 
activity levels in PD and to identify group(s) of patients who increased their activity level the most. 
Multivariate regression showed that a larger change in the level of physical activity was strongly 
associated with less time spent on physical activity at baseline. Once again, this underscores 
the need for a proactive approach towards patients with a very sedentary lifestyle, and who now 
declined to participate in the ParkFit study. 
 Although patients with severe apathy, cognitive impairment or depression were not included in 
the ParkFit study (Chapter 7), therapists reported that patients with cognitive disturbances were 
more difficult to coach towards an active lifestyle. It remains unclear if the ParkFit program is 
also suitable for those patients. Future research and education of physiotherapists should focus 
on coaching patients with co morbidities, cognitive dysfunction and a lack of motivation.
 The success of behavioural change programs depends probably not only on the barriers PD 
patients experience, but also on self-efficacy. Self-efficacy, rather than disability, is strongly as-
sociated with whether community-dwelling PD patients exercise regularly.275 A strength of the 
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ParkFit study is that not only patients who were highly motivated to increase their physical activity 
were included, and that the ParkFit program was individually tailored. Future work should now 
focus on the most effective (individually tailored) programs for PD patients with different bar-
riers and different levels of self-effi cacy to become physically active. Physical therapists should 
include strategies in their coaching to increase self-effi cacy and take into account poor base-
line mobility, physical limitations, baseline physical activity levels, and cognitive functioning of 
patients before starting a behavioral change program in PD patients, for example by engaging 
the immediate caregiver into the program. Perhaps, patients should receive treatment (e.g. by 
increasing dopaminergic medication, or by offering physiotherapy strategies such as cueing) 
prior to participation. 
 The development of appropriate measurements to detect various barriers, including cognitive 
functioning, to become physically active in PD is needed. Furthermore, future work should also 
decide which component of the ParkFit program was most effective, and evaluate if any compo-
nent would also have been effective when used in isolation, and also evaluate which component 
is most effective in different types of patients. 
 The ParkFit study is by far one of the largest randomized controlled trials about physical activity 
in PD patients. Compared with other studies about physical activity, both in PD and other chro-
nic diseases, most available trials have some methodological problems such as a short-term 
follow-up and a low number of patients.68 276 The ParkFit study tackled these problems. What 
sets the ParkFit study apart is: (1) the long term follow-up period of two years; (2) the large 
number of participants included in the study; (3) the challenging combination of both physical 
limitations and cognitive impairments patients with PD are faced with; (4) the pragmatic nature 
and generalizability of the study; the intervention was delivered by not less than 154 different 
physiotherapists, and (5) the low dropout rate of 7.7%. 
 The aim of this thesis was to obtain better insight into the benefi ts, risks and measurements of 
physical activity and exercise in PD, and to develop an approach to stimulate PD patients to a 
sustained, active lifestyle. We have shown that sedentary PD patients were not able to incre-
ase their overall level of physical activity with an individualized behavioral change program. 
However, the secondary endpoints suggest that patient did increased physical activity and im-
proved fi tness, without causing more falls. Although the ParkFit program suggest a sustained 
behavioral change in sedentary PD patients, changing unhealthy behavior still remains a chal-
lenge for patients, therapists and researchers. The evidence about the merits of physical activity 
in patients with PD is still limited. The long-term health benefi ts of physical activity should be 
studied in more detail, with a focus on the optimal dosage, intensity, frequency and duration that 
is needed to achieve clinically meaningful health benefi ts. 
OVERALL CONCLUSION
CHAPTER 11NEDERLANDSESAMENVATTING
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 Dit hoofdstuk geeft een samenvatting van de belangrijkste bevindingen van dit proefschrift. Het 
concentreert zich op de metingen en voordelen van fysieke activiteit bij patiënten met de ziekte 
van Parkinson en hoe patiënten met de ziekte van Parkinson hun niveau van fysieke activiteit 
kunnen verhogen met behulp van een gedragsveranderingsprogramma. 
HOOFDSTUK 2
DE VOORDELEN EN RISICO’S VAN FYSIEKE 
ACTIVITEIT BIJ DE ZIEKTE VAN PARKINSON
 In Hoofdstuk 2 zijn de voordelen en risico’s van meer fysieke activiteit bij de ziekte van Parkinson on-
derzocht. Tien potentiële voordelen van een actieve leefstijl bij patiënten met de ziekte van Parkinson 
zijn geidentifi ceerd namelijk: 1) de preventie van cardiovasculaire complicaties; 2) het vertragen of 
tegenhouden van osteoporose (botontkalking); 3)  het verbeteren van de cognitieve functie; 4) de 
preventie of behandeling van depressie; 5) het verbeteren van het slapen; 6) het verminderen van 
constipatie; 7) het verminderen van vermoeidheid; 8) het verbeteren van de functionele mobiliteit; 9) 
het verbeteren van de doelmatigheid van de parkinsonmedicatie;  en 10) het optimaliseren van het 
dopaminerge systeem. Ondanks dat er veel onderzoek gedaan wordt naar de voordelen van een 
actieve leefstijl, bestaat er nog steeds een gebrek aan bewijs over de voordelen hiervan bij de ziekte 
van Parkinson. Het beste bewijs over de positiefe effecten van fysieke activiteit bestaat voor hart- en 
vaatziekten, cognitief functioneren en stemming. Naast de positieve aspecten van fysieke activiteit 
is het ook van belang om in de gaten te houden of actievere patiënten niet meer gaan vallen, vaker 
valgerelateerde fracturen hebben of vaker cardiovasculaire complicaties ondervinden. 
HOOFDSTUK 3
PREVALENTIE EN RISICOFACTOREN VAN OSTEOPOROSE
 Een van de gezondheidsvoordelen van een actieve leefstijl is het positieve effect op de bot-
massa. Het verlies van botmassa komt vaker voor bij mensen met de ziekte van Parkinson dan 
in de algemene populatie. Er zijn verschillende factoren die betrokken zijn bij dit verlies aan 
botmassa. Daarnaast is osteoporose een belangrijke risicofactor voor het krijgen van fracturen. 
In Hoofdstuk 3 is de prevalentie van osteoporose  en de mogelijke factoren die geassocieerd zijn 
met verlies van botmassa onderzocht bij 191 inactieve patienten met de ziekte van Parkinson. 
 Hoewel er veel onderzoek gedaan wordt is er nog steeds weinig bewijs over de voordelen van 
fysieke activiteit bij patiënten met de ziekte van Parkinson. Op basis van verschillende theore-
tische gronden is het echter wel belangrijk om een actieve leefstijl bij patiënten met, of met het 
risico op, de ziekte van Parkinson te stimuleren. 
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De resultaten laten zien dat 53.2% van de patiënten met de ziekte van Parkinson osteoporose 
hadden. Mensen die minder wegen en een laag vitamine D niveau hebben, hebben meer kans 
op een lagere botdichtheid. Daarnaast hebben vrouwen meer kans op een lagere botdichtheid. 
De vitamine D concentratie werd onderzocht tussen de 191 inactieve patiënten met de ziekte 
van Parkinson en een controlegroep zonder de ziekte van Parkinson. De vitamine D concentratie 
bleek lager te zijn bij mensen met de ziekte van Parkinson in vergelijking met de groep zonder 
de ziekte van Parkinson. 
HOOFDSTUK 4 
PATHOFYSIOLOGIE EN BEHANDELING VAN OSTEOPOROSE
 In Hoofdstuk 4 is de pathofysiologie en behandeling van osteoporose onderzocht doormiddel 
van een literatuurstudie. De resultaten van het literatuuronderzoek laten zien dat de verminde-
ring van de botdichtheid veel verschillende factoren kent. Deze factoren zijn: 1) verminderde 
mobiliteit; 2) tekort aan vitamine D; 3) hyperhomocystenemie (een verhoogde waarde van het 
aminozuur homocysteine in het bloed);  4) tekort aan vitamine B12 of foliumzuur; 5) ondervoe-
ding of een laag lichaamsgewicht; en 6) verminderde spierkracht. De behandeling met bisfos-
fonaten (geneesmiddel ter preventie van osteoporose),  vitamine D en calcium verhogen de 
botdichtheid bij patiënten met de ziekte van Parkinson. Het screenen van patiënten met de ziekte 
van Parkinson op osteoporose zou vaker overwogen moeten worden en een therapeutische be-
handeling moet gestart worden bij die patiënten met bewezen osteoporose. Een adequate be-
handeling van osteoporose zou het risico op fracturen kunnen verminderen, maar de (kosten-)
effectiviteit van deze aanpak moet onderzocht worden.
 Meer dan 50% van de inactieve patiënten met de ziekte van Parkinson hebben een abnormale 
botdichtheid. Mensen die minder wegen en een laag vitamine D niveau hebben, hebben meer 
kans op een lagere botdichtheid. Daarnaast hebben vrouwen meer kans op een lagere botdicht-
heid.  De vitamine D concentratie bleek  lager te zijn bij mensen met de ziekte van Parkinson in 
vergelijking met een controlegroep zonder de ziekte van Parkinson.
 Een verlaagde botdichtheid bij de ziekte van Parkinson is multifactoriaal en bestaat uit een 
verminderde mobiliteit, vitamine D tekort, hyperhomocysteinemia, vitamine B12 of foliumzuur 
tekort, ondervoeding of een laag lichaamsgewicht en een verminderde spierkracht.
HOOFDSTUK 5 
METEN VAN FYSIEKE ACTIVITEIT MET EEN 
ACTIVITEITENMONITOR 
 Het meten van fysieke activiteit in het dagelijks leven is lastig. Er zijn verschillende methodes  beschik-
baar om het niveau van fysieke activiteit of energieverbruik te meten waaronder activiteitenmonitors. 
Het gebruik van activiteitenmonitors bij het langdurig meten van fysieke activiteit of het meten van 
de gelopen afstand is nog beperkt. In Hoofstuk 5 is een simpele activiteitenmonitor die de gelopen 
afstand kan schatten onderzocht bij patiënten met de ziekte van Parkinson. Deze monitor wordt 
gedragen in een riem op de rug en maakt gebruik van tri-axiale accelerometers. De resultaten laten 
zien dat deze monitor korte afstanden (tussen de 20 en 27 meter) precies kan schatten, maar dat 
het schatten van lange afstanden (maximaal 1097 meter) minder precies is. De afwijking van de 
werkelijk gelopen afstand ligt tussen de -42% en 41%. Hierdoor is het gebruik van deze monitor in 
de praktijk beperkt. Als de monitor gebruikt wordt als screeningsmethode, zal de werkelijk gelopen 
afstand de gemeten afstand min of plus 40% zijn.
HOOFDSTUK 6 
CARDIOVASCULAIRE REACTIES BIJ PATIËNTEN
MET DE ZIEKTE VAN PARKINSON
 Patiënten met de ziekte van Parkinson zijn minder fysiek actief in vergelijking met gezonde 
controles. Autonome dysfunctie draagt mogelijk bij aan deze inactieve leefstijl. Mogelijk be-
perken veranderende cardiovasculaire reacties tijdens fysieke inspanning het ondernemen 
van fysieke activiteiten. In Hoofdstuk 6 zijn de cardiovasculaire reacties van patiënten met 
de ziekte van Parkinson tijdens een submaximale inspanningstest op de fi ets vergeleken met 
gezonde controles. Patiënten met de ziekte van Parkinson bleken een lagere geschatte maxi-
male zuurstofopname te hebben vergeleken met gezonde controles (22 ml/min/kg versus 
33 ml/min/kg). Daarnaast was meer dan de helft van de patiënten niet in staat hun hartslag 
adequaat (een hartslag boven de 120 slagen per minuut) te verhogen tijdens de submaxi-
male inspanningstest, terwijl bijna alle gezonde controles hier wel toe in staat waren. Deze 
inadequate verhoging van de hartslag tijdens inspanning wordt mogelijk veroorzaakt door 
autonome dysfunctie. 
 De precisie van de activiteitenmonitor voor het schatten van lange afstanden is onvoldoende ade-
quaat. Daarom is het gebruik van deze activiteitenmonitor voor klinische doeleinden beperkt. 
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HOOFDSTUK 7
RESULTATEN VAN DE PARKFIT STUDIE
 In Hoofdstuk 7 wordt de ParkFit studie beschreven. De ParkFit studie richtte zich op de vraag 
of patiënten met de ziekte van Parkinson met een inactieve leefstijl in staat zijn middels een 
bewegingsbevorderingsprogramma hun niveau van fysieke activiteit te verhogen. Vervolgens 
werd onderzocht wat de mogelijke voordelen of nadelen van meer bewegen waren. Patiënten 
die deelnamen aan het onderzoek werden willekeurig verdeeld over twee fysiotherapeutische 
programma’s. Het ParkFit programma richtte zich op het bevorderen van een actieve leefstijl. 
De patiënten stelden samen met hun coach een beweegplan op met persoonlijke doelstellingen 
voor korte en lange termijn. Daarnaast ontvingen ze een activiteitenmonitor die hen visueel 
stimuleerde fysiek actiever te worden. Het controleprogramma richtte zich op het verbeteren van 
de kwaliteit van leven door verbeteren of behouden van zelfstandigheid, veiligheid en welbevin-
den tijdens bewegen. 
 In totaal werden er 586 patiënten twee jaar lang gevolgd en de verandering in het niveau van 
fysieke activiteit werd tussen de twee groepen vergeleken. De resultaten laten zien dat de tijd die 
besteed werd aan fysieke activiteit vergelijkbaar was tussen de twee groepen (verschil: 7%; 95% 
betrouwbaardheidsinterval -3 tot 17%; p=0.19). Analyses van de secundaire uitkomstmaten lie-
ten echter wel een toename zien van fysieke activiteit bij patiënten die het ParkFit programma 
hadden gevolgd.  Zowel op basis van een beweegdagboek (verschil van 30%; p<0.001), een 
activiteitenmonitor (verschil van 12%; p<0.001), als op de 6 minuten wandeltest (verschil van 4.8 
meter; p=0.05) waren patiënten in het ParkFit programma signifi cant verbeterd ten opzichte van 
de patiënten in het controleprogramma. Kwaliteit van leven gemeten met de PDQ-39 verschilde 
niet tussen beide groepen (verschil van -0.9 punten; p=0.14). Het aantal mensen dat één of 
meerdere keren viel, was vergelijkbaar tussen de twee groepen: ParkFit 62% en controles 67%.
 Het ParkFit programma had geen invloed op het niveau van fysieke activiteit van mensen met de 
ziekte van Parkinson. Echter, de secundaire uitkomstmaten lieten een toename in het activiteiten-
niveau zien evenals een verbetering in fi theid, zónder dat mensen meer gingen vallen.
 De helft van de patiënten met de ziekte van Parkinson heeft een inadequatie verhoging van de 
hartslag tijdens submaximale inspanning, waarschijnlijk veroorzaakt door cardiale sympatische 
denervatie die leidt tot autonome dysfunctie. Deze kennis moet gebruikt worden bij de inter-
pretatie van uitkomsten van inspanningstests tijdens het screenen van bruikbare patiënten voor 
bewegingsprogramma’s. 
HOOFDSTUK 8 
EVALUATIE VAN HET PARKFIT PROGRAMMA
 In Hoofdstuk 8 hebben we de verschillende elementen van het ParkFit programma geëvalueerd die 
relevant zijn voor toekomstige implementatie van het programma in de praktijk. Hiervoor zijn er 
vier verschillende elementen gemeten: 1) de ervaringen van patiënten en therapeuten met het pro-
gramma middels vragenlijsten en interviews; 2) factoren die geassocieerd zijn met een verandering 
van het niveau van fysieke activiteit; en 3) analyses om effecten in verschillende subgroepen van 
patiënten te inventariseren; de indeling in subgroepen was gebaseerd op de volgende variabelen: 
niveau van fysieke activiteit op baseline; leeftijd; geslacht; ziekte ernst; ziekteduur; en mobiliteit 
van de patiënt.
 Data van 255 patiënten (85%) en 116 (97%) fysiotherapeuten werden geanalyseerd. Zowel pa-
tiënten en therapeuten zijn positief over de interventie. Bijna alle therapeuten (90%) geven aan 
het ParkFit programma ook graag bij andere patiënten te willen gebruiken, 73% van de patiënten 
zouden het ParkFit programma aanbevelen aan andere patiënten. Aanbevelingen voor verdere 
implementatie zijn: 1) de behoeft aan (meer) scholing op het gebied van coaching en gedragsver-
anderingstechnieken; en 2) (meer) advies over het verhogen van het niveau van fysieke activiteit in 
specifi eke groepen patiënten ( bijvoorbeeld patiënten met comorbiditeiten). 
 Een lager niveau van fysieke activiteit op baseline en een hoger niveau van mobiliteit waren 
geassocieerd met een hogere toename van fysieke activiteit gedurende twee jaar (R2=48%). De 
subgroepanalyse laat zien dat het programma effectief is in bijna alle subgroepen. De meest inac-
tieve patiënten, vrouwen, patiënten met een lagere baselinescore op de UPDRS, patiënten met een 
korte ziekte duur en oudere patiënten lijken het meeste voordeel te hebben van het programma. 
 Het ParkFit programma verhoogde het niveau van fysieke activiteit in bijna alle subgroepen van 
patiënten. Therapeuten en patiënten hadden geen grote belemmeringen ervaren voor verdere 
implementatie van het ParkFit programma. 
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 ‘Niet volmaakt is eerder perfect’.  Als onderzoeker is dit soms moeilijk te geloven. De afgelopen 
jaren heb ik, weliswaar met vallen en opstaan, gestreefd naar het perfecte onderzoek. Jaren 
waarin ik ontzettend veel heb geleerd, hebben geleid tot dit eindresultaat, mijn proefschrift! 
 Er zijn veel mensen die hebben bijgedragen aan het realiseren van dit proefschrift op verschil-
lende manieren. Het begint bij de kans die je krijgt om onderzoek te doen, patiënten die zich 
inzetten om aan onderzoek mee te werken en de nodige hulp bij het schrijven van je artikelen. 
Mijn dank gaat dan ook uit naar iedereen die een bijdrage hebben geleverd aan de tot stand-
koming van dit proefschrift. 
 Een aantal personen verdienen een speciaal woord van dank:
ALLE PATIËNTEN EN FYSIOTHERAPEUTEN DIE HEBBEN DEELGENOMEN AAN HET ONDERZOEK,
 we hebben twee jaar lang veel van jullie gevraagd. Ik hoop dat we het onderzoek voor jullie in 
goede banen hebben kunnen leiden. Bedankt voor alle energie en tijd die jullie er in hebben 
gestoken. 
MARLIES,
 het was een sprong in het diepe enige jaren geleden. Ik ben heel bij dat ik dit samen met jou 
heb mogen doen. Ik heb ontzettend veel mét en van je geleerd. We hadden een enorme klus te 
klaren, en dat ging niet altijd vanzelf. Gelukkig ging onze samenwerking vaak wel als vanzelf, 
meestal hadden we aan één woord genoeg. Daarnaast  waren deze jaren veel leuker samen 
met jou dan alleen! Al die jaren hebben we naast elkaar gestaan en het kan dan ook niet anders 
dat jij op deze dag ook naast me staat als mijn paranimf. 
BAS EN MARTEN,
 mijn promotor en copromotor. Begonnen als student en nu geeindigd als onderzoeker, zonder 
jullie had ik deze stap niet kunnen nemen. Ik heb veel van jullie geleerd afgelopen jaren, voor-
namelijk om ‘groot’ te denken. De manier waarop jullie altijd positief en zonder beperkingen 
tegen nieuwe dingen aankijken zal me altijd bijblijven. 
FRANK,
 mijn tweede promotor. Vanaf het begin betrokken bij de aanvraag. Bedankt voor je sportge-
neeskundige input tijdens het hele proces. Daarnaast is mede door jouw betrokkenheid de 
samenwerking tussen Nijmegen en Utrecht tot stand gekomen, bedankt daarvoor. 
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BART,
 mijn tweede copromotor. Je bent wat later op mijn pad gekomen, maar je betrokkenheid was er 
niet minder om. Ik heb ontzettend prettig met je samen gewerkt. Bedankt voor je interesse en je 
altijd snelle en heldere feedback.
GEORGE,
 wat moet een promovendus zonder jou als statisticus. Bedankt voor je altijd kritische blik en 
discussies tijdens de gezamenlijke bijeenkomsten.  Het is heel prettig hoe je van een hoop on-
duidelijke cijfers en analyses weer een heel helder geheel kunt maken. Dat heeft me elke keer 
weer nieuwe energie gegeven. 
DE LEDEN VAN DE MANUSCRIPTCOMMISSIE,
 –Ria Nijhuis-van der Sanden, Bob van Hilten en Marijke Hopman-Rock– dank ik hartelijk 
voor de inhoudelijke beoordeling van mijn manuscript. 
ALLE LEDEN VAN DE PROJECTGROEP EN DE ADVIESRAAD VAN DE PARKFIT STUDIE,
 wil ik heel erg bedanken voor alle goede adviezen tijdens de opzet en uitvoering van de studie. 
Alle coauteurs van de verschillende artikelen wil ik bedanken voor het lezen, aanvullen en 
kritische commentaar op de artikelen. Bedankt voor de fijne samenwerking. 
DE ONDERZOEKSASSISTENTEN,
 Karin, Mirte, Anita, Thijs, Ine en Marloes. Heel erg veel dank voor al jullie inzet! 
 Tia, Marije en Willeke, zonder jullie geen onderzoek. Jullie hebben het niet altijd makkelijk 
gehad met ons, als we weer eens met een nieuw in te vullen schema aankwamen, 600 brieven 
de deur uitmoesten, 150 therapeuten gebeld moesten worden of als jullie in alle vroegte met 
de witte citroën saxo op pad moesten! Bedankt voor de bergen werk die jullie voor ons verzet 
hebben. Het was ontzettend fijn om jullie als onderzoeksassistenten te hebben. 
ALLE STAGIAIRES EN ALLE STUDENTEN,
 van de opleiding Fysiotherapie en Sport, Gezondheid en Management van de HAN die stage 
hebben gelopen bij de ParkFit studie de afgelopen jaren. Heel erg bedankt voor jullie inzet, tijd 
en energie die jullie hebben gestoken in het meten van alle patiënten, het invoeren van data en 
de vele telefoontjes die jullie hebben gepleegd. 
 ALLE COLLEGA’S VAN DE AFDELING NEUROLOGIE EN ONDERZOEKERS VAN PARC,
 wat heeft een promovendus naast goede begeleiding nog meer nodig? Fijne collega’s die 
altijd in zijn voor een discussie over vele uiteenlopende zaken! Gelukkig hebben we naast onze 
drukke werkzaamheden toch momenten weten te vinden om ons werk ook eens van de andere 
kant te bekijken. 
KATRIJN,
 wat was het fijn om jou als collega en kamergenoot te hebben. Ik heb veel geleerd van je altijd 
heerlijke kritische blik op onderzoek en ontzettend met en om je gelachen. Never a dull moment 
with you! Gelukkig is het nu eindelijk tijd voor je sketch, ik kan niet wachten. 
MIJN LIEVE FAMILIE EN VRIENDINNEN,
 ook jullie hebben een belangrijke bijdrage geleverd aan dit proefschrift. Het promoveren stond 
misschien soms ver van jullie af, maar een andere kijk op de zaak geeft soms zoveel meer inzicht. 
Gelukkig konden jullie altijd hartelijk lachen om alle promotieperikelen, dat helpt relativeren! 
 Anke en Margit, bedankt voor alle vele gezellige uurtjes samen de afgelopen jaren. 
 Dat er nog vele etentjes mogen volgen. 
LIEVE MARINA,
 allereerst bedankt voor je vriendschap, voor dat je er altijd voor me bent en voor wie je bent. Ik 
kan altijd rekenen op je steun (ik weet niet hoeveel belminuten er door heen gegaan zijn),  hard 
met je lachen, of bijkletsen met een kopje thee op de bank. Bedankt voor alle leuke dingen die 
we samen hebben mogen meemaken en nog gaan meemaken. Ik ben dan ook heel blij dat jij 
op deze dag mijn paranimf wilt zijn. 
LIEVE CLAUDIA EN STEFAN,
 wat fijn dat ik zo’n lieve zus en broer(tje) heb. Bedankt voor jullie steun, goede zorgen en inte-
resse in mijn onderzoek. Ondanks dat jullie allemaal naar het hoge Noorden vertrokken zijn 
zien we elkaar gelukkig nog regelmatig, al is het soms via de webcam. Als ik Jilia weer lief in de 
camera heb zien lachen is mijn dag altijd weer goed, maar liever natuurlijk de ‘live’ knuffels! 
 Nynke Hester en Riemer, ik ben blij met jullie als ‘schoon-’ broer en zus. 
LIEVE PAPA EN MAMA,
 meer dan ooit besef ik me hoeveel jullie voor mij doen. Jullie hebben me altijd gestimuleerd het 
beste uit mezelf te halen en voor het hoogst haalbare te gaan. Bedankt voor alle goede zorgen, 
gevraagd en ongevraagd, steun en alle mogelijkheden die jullie me hebben gegeven.  
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